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ABSTRACT 
 
Objective: To identify gaps in the economic literature as it pertains to kidney 
transplantation in order to inform future research topics as well as to identify the most 
cost-effective national screening policy for high-infectious risk organ donors and the 
most cost-effective utilization of marginal quality donated kidneys. 
 
Methods: A scoping review was employed to review the economics and kidney 
transplantation literature in order to perform a research gaps analysis.  A decision tree 
analysis was used to elucidate the most cost-effective high-infectious risk donor 
screening strategy and a Markov model was utilized to determine patient phenotypes that 
would benefit from marginal quality kidney donor organs as well as the cost-
effectiveness of accepting certain quality organs for specific patient phenotypes. 
 
Results: The scoping review identified 278 articles from 102 medical and economic 
journals with research gaps including patient-perspective, pediatrics, and 
structural/macroeconomic topics. The decision tree analysis found that Selected NAT 
with ELISA screening strategy was the most cost-effective with an $18,100 savings per 
QALY compared to the current screening practice (discarding the ELISA Only strategy 
as a strategy that would not be employed in real practice) . The Markov model identified 
a large number of patient phenotypes that benefited from high KDPI organ acceptance 
with increased survival and QALYs and decreased lifetime treatment costs. 
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Conclusion: Evaluation of the literature related to economics in kidney transplantation 
afforded the opportunity to address directed research by identifying future research 
efforts based on formal gaps analysis. The scarcity of organs in transplantation offered a 
rich opportunity to explore the related economic concepts of individual welfare 
maximization, allocation efficiency, and cost-effective analysis of competing screening 
strategies. The results of this dissertation may have policy impacts regarding the funding 
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CHAPTER	  ONE	  –END-­‐STAGE	  RENAL	  DISEASE	  AND	  RENAL	  TRANSPLANTATION	  
	  
Chronic	  disease	  in	  the	  U.S.	  continues	  to	  increase	  in	  prevalence	  and	  constitutes	  a	  
major	  fiscal	  burden.	  Chronic	  diseases	  accounted	  for	  seven	  of	  the	  top	  ten	  causes	  of	  
death	  in	  20101	  and	  constituted	  about	  78%	  of	  health	  care	  spending.2	  There	  has	  been	  
a	  concerted	  national	  effort	  to	  address	  chronic	  diseases	  underlined	  by	  the	  existence	  
of	  a	  National	  Center	  for	  Chronic	  Disease	  Prevention	  and	  Health	  Promotion.3	  Chief	  
among	  these	  chronic	  diseases	  are	  cancers,	  hypertension	  and	  diabetes.2	  Two	  of	  the	  
top	  chronic	  diseases,	  diabetes	  and	  hypertension,	  are	  the	  leading	  causes	  of	  chronic	  
kidney	  disease,	  accounting	  for	  up	  to	  67%	  of	  cases.4	  	  
	  
As	  part	  of	  the	  national	  effort	  to	  combat	  chronic	  diseases,	  and	  chronic	  kidney	  disease	  
in	  specific,	  there	  have	  been	  two	  major	  steps	  taken	  by	  the	  U.S.	  government.	  First,	  
Congress	  enacted	  the	  Medicare	  end-­‐stage	  renal	  disease	  entitlement	  in	  1972	  
designed	  to	  more	  readily	  help	  treat	  chronic	  kidney	  disease	  that	  progressed	  to	  renal	  
failure.5	  Second,	  Healthy	  People	  2020,	  the	  United	  States	  government’s	  set	  of	  national	  
health	  goals,	  has	  established	  objectives	  that	  deal	  specifically	  with	  combating	  chronic	  
kidney	  disease.6	  	  
	  
End-­‐stage	  renal	  disease	  	  (ESRD)	  is	  one	  of	  the	  natural	  consequences	  of	  chronic	  
kidney	  disease	  and	  is	  defined	  by	  the	  Centers	  for	  Medicare	  and	  Medicaid	  Services	  as	  
stage	  V	  chronic	  kidney	  disease	  (CKD)	  that	  requires	  a	  regular	  course	  of	  dialysis	  or	  a	  
kidney	  transplantation	  to	  improve	  one’s	  quality	  of	  life.7	  A	  national	  database,	  the	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United	  States	  Renal	  Data	  System,	  records	  all	  those	  with	  CKD	  and	  ESRD	  and	  is	  funded	  
by	  the	  National	  Institute	  of	  Diabetes	  and	  Digestive	  and	  Kidney	  Diseases	  which	  in	  
turn	  collaborates	  with	  the	  Centers	  for	  Medicare	  &	  Medicaid	  Services,	  UNOS	  and	  
other	  ESRD	  networks	  to	  provide	  up-­‐to-­‐date	  and	  accurate	  information.8	  In	  2012,	  
there	  were	  114,813	  new	  cases	  of	  ESRD	  (a	  3.7%	  decrease	  from	  2011)	  and	  636,905	  
were	  receiving	  treatment	  for	  ESRD	  via	  dialysis	  or	  transplantation	  (a	  3.7%	  increase	  
from	  2011).6	  	  
	  
Overall	  mortality	  continues	  to	  decrease	  in	  ESRD	  patients	  with	  88,638	  ESRD	  patients	  
passing	  away	  during	  2012.6	  Morbidity	  in	  ESRD	  includes	  feeling	  “unwell”	  as	  the	  body	  
accumulates	  fluid	  of	  which	  it	  cannot	  dispose	  thereby	  creating	  an	  electrolyte	  
imbalance,	  the	  need	  to	  spend	  hours	  at	  a	  dialysis	  center	  three	  times	  a	  week,	  the	  need	  
to	  undergo	  an	  operation	  for	  a	  transplantation,	  the	  need	  to	  take	  immunosuppression	  
medication	  after	  transplantation,	  infectious	  complications	  from	  surgery	  or	  from	  
dialysis	  catheter,	  and	  continual	  need	  for	  arteriovenous	  graft/fistula	  or	  central	  line	  
revisions.	  A	  recent	  meta-­‐analysis	  of	  quality-­‐adjusted	  life	  years	  (QALYs)	  in	  those	  with	  
chronic	  kidney	  disease	  reported	  QALYS	  of	  0.82	  (95%	  CI:	  0.74-­‐0.90)	  for	  those	  with	  
renal	  transplants	  and	  0.69	  (95%	  CI:	  0.59-­‐0.80)	  for	  those	  undergoing	  hemodialysis.9	  
	  
Those	  with	  ESRD	  are	  entitled	  to	  coverage	  by	  Medicare	  and	  this	  coverage	  starts	  on	  
the	  first	  day	  of	  the	  fourth	  month	  of	  dialysis	  treatments	  (this	  waiting	  period	  starts	  
even	  if	  the	  individual	  has	  not	  applied	  to	  Medicare)	  unless	  the	  individual	  takes	  part	  
in	  a	  home	  dialysis	  training	  program	  or	  has	  a	  physician	  verify	  that	  they	  expect	  the	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individual	  to	  be	  able	  to	  finish	  training	  and	  administer	  their	  own	  dialysis	  treatments	  
in	  which	  case	  the	  coverage	  would	  start	  in	  the	  first	  month	  of	  dialysis.5	  Medicare	  
coverage	  ends	  12	  months	  after	  the	  month	  of	  dialysis	  cessation	  or	  36	  months	  after	  a	  
kidney	  transplant.5	  Total	  Medicare	  claims	  paid	  for	  those	  with	  ESRD	  in	  2012	  were	  
$28.6	  billion,	  which	  was	  3.5%	  higher	  than	  2011,	  and	  accounted	  for	  5.6%	  of	  the	  
Medicare	  budget	  while	  the	  ESRD	  population	  accounts	  for	  les	  than	  1%	  of	  the	  total	  
Medicare	  population.6	  	  
	  
During	  2012,	  there	  were	  17,330	  renal	  transplants	  with	  5,617	  coming	  from	  living	  
donors	  to	  give	  a	  total	  prevalence	  of	  those	  with	  renal	  transplants	  of	  175,978.6	  During	  
the	  same	  year,	  28,867	  ESRD	  patients	  were	  added	  to	  the	  transplant	  waiting	  list	  (both	  
kidney	  and	  kidney/pancreas)	  and	  the	  median	  time	  on	  the	  waitlist	  was	  3.31	  years.6	  	  
	  
Waiting	  list	  priorities	  are	  based	  on	  a	  point	  system	  that	  includes	  sensitization	  (the	  
calculated	  panel	  reactive	  antibody	  is	  used	  to	  express	  the	  expected	  percentage	  of	  
donors	  that	  will	  have	  one	  or	  more	  unacceptable	  antigens	  for	  the	  candidate),	  time	  on	  
the	  wait	  list	  starting	  when	  the	  glomerular	  filtration	  rate	  is	  less	  than	  or	  equal	  to	  20	  
mL/min/1.73m2,	  age,	  if	  the	  candidate	  was	  a	  prior	  living	  donor,	  human	  leukocyte	  
antigen	  (HLA)	  matching,	  estimated	  post	  transplant	  survival	  (based	  on	  time	  on	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A	  Brief	  History	  of	  Transplantation	  
The	  first	  successful	  kidney	  transplantation	  occurred	  in	  1954	  between	  identical	  twin	  
brothers	  at	  the	  Brigham	  Hospital	  in	  Boston,	  Massachusetts.	  It	  was	  not	  until	  1960	  
that	  a	  successful	  kidney	  transplantation	  was	  performed	  between	  non-­‐twin	  
siblings.11	  The	  advent	  of	  immunosuppressive	  medications	  was	  a	  significant	  moment	  
in	  transplantation.	  While	  the	  discovery	  of	  cyclosporine’s	  ability	  to	  suppress	  the	  
human	  immune	  system	  (and	  thereby	  prevent	  organ	  rejection	  in	  transplantation)	  
was	  in	  1976,	  it	  was	  not	  until	  1983	  that	  the	  Food	  and	  Drug	  Administration	  approved	  
its	  use	  in	  transplantation.11	  
	  
The	  first	  organ	  procurement	  organization	  (OPO)	  was	  organized	  in	  1968	  in	  Boston	  
(the	  New	  England	  Organ	  Bank).11	  That	  same	  year,	  1968,	  the	  National	  Conference	  of	  
Commissioners	  on	  Uniform	  State	  Laws	  established	  the	  Uniform	  Donor	  Card	  as	  a	  
legal	  document	  in	  all	  50	  states	  through	  the	  Uniform	  Anatomical	  Gift	  Act	  that	  enabled	  
anybody	  over	  the	  age	  of	  18	  to	  legally	  donate	  their	  organs	  by	  legal	  consent	  prior	  to	  
death	  as	  well	  as	  identify	  the	  hierarchy	  of	  individuals	  that	  could	  donate	  another	  
deceased	  person’s	  organs.11	  In	  1973,	  Congress	  amended	  the	  Social	  Security	  Act	  to	  
provide	  Medicare	  coverage	  to	  selected	  individuals	  with	  chronic	  renal	  disease.12	  
Then	  it	  was	  in	  1984	  that	  Congress	  enacted	  the	  National	  Organ	  Transplant	  Act	  
(NOTA)	  which	  prohibited	  the	  trafficking	  of	  human	  organs,	  established	  the	  OPTN	  
(tasked	  with	  assuring	  fair	  and	  equitable	  organ	  allocation	  along	  with	  setting	  
membership	  criteria	  for	  transplant	  centers)	  and	  established	  the	  Scientific	  Registry	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of	  Transplant	  Recipients	  (SRTR,	  assigned	  to	  perform	  ongoing	  evaluation	  of	  the	  
scientific	  and	  clinical	  outcomes	  of	  organ	  transplantation).11	  Although	  the	  OPTN	  was	  
established	  in	  1984,	  it	  was	  not	  until	  1986	  when	  the	  first	  contract	  to	  operate	  the	  
OPTN	  was	  awarded	  by	  the	  U.S.	  Department	  of	  Health	  and	  Human	  Services	  to	  the	  
United	  Network	  for	  Organ	  Sharing	  (UNOS).11	  UNOS	  is	  a	  private,	  non-­‐profit	  
organization	  that	  is	  tasked	  with	  managing	  the	  transplant	  waiting	  list,	  matching	  
donors	  to	  recipients	  and	  maintaining	  a	  database	  of	  all	  transplants.	  In	  order	  to	  help	  
with	  there	  task,	  in	  1989	  UNOS	  established	  11	  regions	  of	  the	  country	  run	  by	  69	  
OPO’s.13-­‐15	  
	  
Future	  Research	  Directions	  in	  Transplantation	  
Transplantation	  is	  the	  treatment	  associated	  with	  the	  highest	  survival	  and	  quality	  of	  
life	  for	  those	  with	  ESRD.6	  In	  fact,	  it	  has	  been	  known	  since	  at	  least	  1968	  that	  kidney	  
transplantation	  is	  the	  most	  cost-­‐effective	  treatment	  of	  end-­‐stage	  renal	  disease.17	  The	  
question	  then	  becomes	  how	  to	  best	  utilize	  the	  scarce	  resource	  of	  donated	  kidneys	  in	  
treating	  ESRD.	  	  The	  importance	  of	  this	  question	  is	  underlined	  by	  the	  recent	  
reallocation	  policies	  adopted	  by	  the	  OPTN,	  namely	  the	  Share	  35	  for	  kidneys	  in	  2005	  
and	  Share	  35	  for	  livers	  in	  2013.	  During	  an	  era	  of	  cost	  conscious	  healthcare,	  
economics	  is	  an	  effective	  research	  tool	  in	  determining	  both	  optimum	  outcomes	  and	  
cost-­‐effectiveness	  in	  the	  setting	  of	  scarce	  resources.	  Lionel	  Robbins,	  a	  former	  head	  
of	  the	  economics	  department	  at	  the	  London	  School	  of	  Economics,	  gave	  his	  famous	  
definition	  of	  economics	  as	  “the	  science	  which	  studies	  human	  behaviour	  as	  a	  
relationship	  between	  ends	  and	  scarce	  means	  which	  have	  alternative	  uses”	  in	  his	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1932	  Essay	  on	  the	  Nature	  and	  Significance	  of	  Economic	  Science.18	  The	  advantages	  of	  
using	  economics	  rather	  than	  only	  statistical	  analysis	  of	  allocation	  efficiency	  is	  that	  
economics	  can	  evaluate	  efficiency	  based	  on	  a	  number	  of	  parameters	  including	  
survival,	  cost,	  and	  utility	  as	  they	  pertain	  to	  individuals	  and	  societies.	  	  This	  thesis	  
endeavors,	  in	  part,	  to	  address	  or	  improve	  efficient	  allocation	  of	  donor	  kidneys	  in	  


















	   	  




1.	   Centers	  for	  Disease	  Control	  and	  Prevention.	  Chronic	  Disease	  Prevention	  and	  
Health	  Promotion.	  2014;	  
http://www.cdc.gov/chronicdisease/overview/index.htm#ref1.	  Accessed	  
April	  6,	  2015.	  
2.	   Bodenheimer	  T,	  Chen	  E,	  Bennett	  H.	  Confronting	  The	  Growing	  Burden	  of	  
Chronic	  Disease:	  Can	  the	  U.S.	  Health	  Care	  Workforce	  Do	  The	  Job?	  Health	  Aff.	  
2009;28(1):64-­‐74.	  
3.	   Centers	  for	  Disease	  Control	  and	  Prevention.	  Preventing	  Chronic	  Disease:	  
Public	  Health	  Research,	  Practice,	  and	  Policy:	  About	  the	  Journal.	  2015;	  
http://www.cdc.gov/pcd/about_the_journal/.	  Accessed	  April	  6,	  2015.	  
4.	   National	  Kidney	  Foundation.	  About	  Chronic	  Kidney	  Disease.	  2015;	  
https://www.kidney.org/kidneydisease/aboutckd.	  Accessed	  April	  6,	  2015.	  
5.	   Centers	  for	  Medicare	  &	  Medicaid	  Services.	  How	  to	  Sign	  up	  for	  Medicare	  if	  you	  
have	  End-­‐Stage	  Renal	  Disease	  (ESRD).	  	  http://www.medicare.gov/people-­‐
like-­‐me/esrd/getting-­‐medicare-­‐with-­‐esrd.html#collapse-­‐3178.	  Accessed	  
February	  27,	  2015.	  
6.	   US	  Renal	  Data	  System.	  USRDS	  2014	  Annual	  Data	  Report:	  Atlas	  of	  Chronic	  
Kidney	  Disease	  and	  End-­‐Stage	  Renal	  Disease	  in	  the	  United	  States,	  National	  
Institutes	  of	  Health,	  National	  Institute	  of	  Diabetes	  and	  Digestive	  and	  Kidney	  
Diseases.	  2014;	  http://www.usrds.org/2014/view/v2_05.aspx.	  
	   	  
	   8	  
7.	   Centers	  for	  Medicare	  &	  Medicaid	  Services.	  2013	  National	  Training	  Program.	  	  
Module	  6:	  Medicare	  for	  People	  with	  End-­‐Stage	  Renal	  Disease.	  Department	  of	  
Health	  and	  Human	  Services	  2013;	  https://www.cms.gov/Outreach-­‐and-­‐
Education/Training/CMSNationalTrainingProgram/Downloads/2013-­‐
Medicare-­‐for-­‐People-­‐with-­‐End-­‐Stage-­‐Renal-­‐Disease-­‐Workbook.pdf.	  Accessed	  
March	  30,	  2015.	  
8.	   United	  States	  Renal	  Data	  System.	  United	  States	  Renal	  Data	  System.	  2015;	  
http://www.usrds.org/.	  Accessed	  June	  4,	  2015.	  
9.	   Wyld	  M,	  Morton	  RL,	  Hayen	  A,	  Howard	  K,	  Webster	  AC.	  A	  systematic	  review	  
and	  meta-­‐analysis	  of	  utility-­‐based	  quality	  of	  life	  in	  chronic	  kidney	  disease	  
treatments.	  PLoS	  Med.	  2012;9(9):e1001307.	  
10.	   U.S.	  Department	  of	  Health	  &	  Human	  Services.	  Organ	  Procurement	  and	  
Transplantation	  Network	  Policies.	  	  
http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf.	  
Accessed	  February	  27,	  2015.	  
11.	   U.S.	  Department	  of	  Health	  &	  Human	  Services.	  Timeline	  of	  Historical	  Events	  
Significant	  Milestones	  in	  Organ	  Donation	  and	  Transplantation.	  	  
http://www.organdonor.gov/legislation/timeline.html.	  Accessed	  February	  
27,	  2015.	  
12.	   U.S.	  Department	  of	  Health	  &	  Human	  Services.	  Selected	  Statutory	  and	  
Regulatory	  History	  of	  Organ	  Transplantation.	  	  
http://www.organdonor.gov/legislation/legislationhistory.html.	  Accessed	  
February	  27,	  2015.	  
	   	  
	   9	  
13.	   United	  Network	  for	  Organ	  Sharing.	  About	  Us.	  	  
http://www.unos.org/about/index.php.	  Accessed	  February	  27,	  2015.	  
14.	   United	  Network	  for	  Organ	  Sharing.	  UNOS	  History.	  	  
http://www.unos.org/about/index.php?topic=history.	  Accessed	  February	  27,	  
2015.	  
15.	   Kidney	  Link.	  OPO's	  and	  UNOS.	  	  
http://www.kidneylink.org/OPOsandUNOS.aspx.	  Accessed	  February	  27,	  
2015.	  
16.	   Kandaswamy	  R,	  Skeans	  M,	  Gustafson	  S,	  et	  al.	  OPTN/SRTR	  2013	  Annuial	  Data	  
Report.	  Americal	  Journal	  of	  Transplantation.	  2015;15(S2):4-­‐13.	  
17.	   Klarman	  H,	  Francis	  J,	  Rosenthal	  G.	  Cost	  Effectiveness	  Analysis	  Applied	  to	  the	  
Treatment	  of	  Chronic	  Renal	  	  Disease.	  Medical	  Care.	  1968;6(1):48-­‐54.	  
18.	   Robbins	  L.	  An	  Essay	  on	  the	  Nature	  and	  Significance	  of	  Economic	  Science.	  










	   	  
	   10	  
CHAPTER	  TWO	  –	  MANUSCRIPT	  #1	  
	  




Objectives:	  	  To	  systematically	  review	  the	  literature	  related	  to	  the	  economic	  
evaluation	  of	  kidney	  transplantation	  in	  order	  to	  determine	  the	  extent	  of	  current	  
research	  and	  identify	  gaps	  for	  future	  research.	  
	  
Data	  Sources:	  	  We	  searched	  4	  medical	  and	  1	  economic	  electronic	  databases.	  	  All	  
searches	  were	  from	  the	  earliest	  dates	  available	  through	  September	  13,	  2014.	  	  
Additional	  articles	  were	  identified	  via	  hand-­‐searching	  reference	  lists	  of	  review	  
articles	  and	  other	  pertinent	  articles.	  
	  
Study	  Selection	  and	  Data	  Extraction:	  	  Articles	  were	  included	  that	  dealt	  with	  an	  
economic	  evaluation	  of	  human	  kidney	  transplantation.	  	  Exclusion	  criteria	  included	  
articles	  that	  did	  not	  include	  original	  work	  (i.e.	  reviews),	  were	  not	  in	  English	  and	  
were	  not	  journal	  articles	  or	  economic	  working	  papers	  (e.g.	  commentaries,	  theses,	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Trevor	  A	  Ellison	  MD	  (1,2);	  Ilene	  L	  Hollin,	  MPH	  (2);	  John	  FP	  Bridges	  PhD	  (2)	  
(1)	  Department	  of	  Surgery,	  Johns	  Hopkins	  University	  School	  of	  Medicine,	  Baltimore,	  MD;	  	  (2)	  
Department	  of	  Health	  Policy	  and	  Management,	  Johns	  Hopkins	  School	  of	  Public	  Health,	  Baltimore,	  MD	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abstracts).	  	  Full	  text	  data	  abstraction	  included	  qualitative	  and	  quantitative	  
parameters	  with	  the	  intent	  to	  perform	  a	  gaps	  analysis	  for	  future	  research.	  	  
	  
Data	  Synthesis:	  	  A	  total	  of	  278	  articles	  were	  included	  and	  they	  spanned	  a	  46-­‐year	  
period	  from	  1968-­‐2014	  with	  over	  70%	  published	  after	  1999.	  	  The	  most	  common	  
topics	  included	  immunosuppression	  drugs,	  infectious	  disease	  prophylaxis,	  dialysis	  
versus	  kidney	  transplantation,	  organ	  allocation	  and	  the	  potential	  market	  for	  donor	  
organs.	  	  The	  majority	  of	  articles	  were	  from	  the	  United	  States	  and	  they	  originated	  
from	  68	  medical	  journals	  and	  34	  economic	  journals	  or	  working	  paper	  centers.	  	  
There	  were	  51	  articles	  dealing	  with	  costing,	  149	  utilizing	  cost-­‐effectiveness,	  65	  
employing	  economic	  modeling,	  3	  performing	  systematic	  reviews	  with	  meta-­‐
analyses	  and	  10	  exploring	  the	  qualitative	  financial	  environment	  of	  individuals	  and	  
the	  economy.	  	  Research	  gaps	  were	  identified	  in	  every	  parameter	  used	  to	  evaluate	  
the	  studies	  and	  a	  new	  system	  of	  gaps	  analysis	  for	  scoping	  reviews	  was	  also	  
proposed.	  
	  
Conclusions:	  	  The	  field	  of	  economic	  evaluation	  in	  kidney	  transplantation	  is	  still	  in	  a	  
relatively	  early	  stage.	  	  The	  research	  gaps	  identified	  through	  this	  study	  provide	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Introduction	  
End-­‐stage	  renal	  disease	  (ESRD)	  is	  defined	  as	  renal	  failure	  requiring	  dialysis	  or	  
transplantation	  for	  patient	  survival	  or	  an	  estimated	  glomerular	  filtration	  rate	  less	  
than	  15	  mL/min/1.73m2	  1and	  it	  affects	  over	  590,000	  individuals	  in	  the	  United	  States	  
with	  over	  116,000	  new	  ESRD	  patients	  each	  year.2	  	  ESRD	  carries	  a	  mortality	  similar	  
to	  that	  of	  an	  early/mid-­‐stage	  lung	  cancer	  at	  five	  years3,4	  and	  the	  main	  contributors	  
to	  the	  continuously	  rising	  rate	  of	  ESRD	  are	  diabetes	  (44%)	  and	  hypertension	  
(28%).2	  Each	  year,	  over	  $47	  billion	  is	  spent	  on	  ESRD	  care	  with	  Medicare	  spending	  
about	  $87,000	  per	  year	  per	  patient	  on	  hemodialysis	  and	  about	  $33,000	  per	  patient	  
per	  year	  after	  a	  kidney	  transplantation.2	  Kidney	  transplantation	  provides	  improved	  
survival,	  better	  quality	  of	  life	  and	  lower	  cost	  of	  care	  compared	  to	  dialysis	  in	  ESRD	  
patients5,6	  and	  the	  main	  problem	  facing	  the	  transplantation	  community	  is	  the	  lack	  of	  
available	  donor	  organs.	  	  From	  2009	  to	  2010,	  adult	  kidney	  transplants	  only	  increased	  
by	  0.8%	  to	  a	  total	  of	  16,843	  while	  the	  waitlist	  increased	  by	  6%	  to	  86,620.2	  As	  kidney	  
transplantation	  is	  the	  most	  cost-­‐effective	  way	  to	  alleviate	  the	  mortality	  and	  
morbidity	  of	  ESRD,	  the	  question	  becomes	  how	  to	  use	  the	  scarce	  resources	  of	  
donated	  kidneys	  most	  effectively	  and	  efficiently	  within	  the	  budget	  constraints	  of	  
Medicare	  and	  society.	  	  	  
	  
Economic	  evaluation	  addresses	  the	  restrained	  optimization	  of	  resources	  premise	  
and	  has	  been	  used	  in	  the	  literature	  to	  address	  issues	  including	  elephant	  poaching,7	  
traffic	  congestion,8	  epilepsy	  surgery,9	  and	  	  lung	  cancer	  management	  in	  the	  era	  of	  
personalized	  medicine.10	  Economic	  evaluation	  also	  has	  been	  used	  in	  the	  kidney	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transplantation	  literature	  to	  assess	  new	  technologies,	  donor	  initiatives,	  markets	  for	  
organs	  and	  the	  use	  of	  expanded	  criteria	  donor	  kidneys,	  to	  name	  a	  few	  instances.	  	  
These	  studies	  vary	  widely	  in	  topic,	  economic	  evaluation	  technique,	  cohorts	  and	  
study	  parameters.	  	  
	  
The	  evaluation	  of	  an	  entire	  field	  of	  literature	  with	  the	  identification	  of	  research	  gaps	  
in	  order	  to	  prioritize	  future	  research	  is	  an	  increasingly	  important	  endeavor	  meant	  
to	  assure	  future	  research	  efforts	  are	  optimized	  instead	  of	  carried	  out	  in	  the	  
traditional	  ad	  hoc	  approach.11-­‐13	  Traditionally,	  journal	  articles	  have	  pointed	  out	  
areas	  of	  future	  research	  based	  on	  concurrently	  discovered	  research	  gaps	  in	  the	  
Discussion	  sections	  as	  closing	  thoughts.	  	  It	  is	  now	  recognized	  that	  research	  gaps	  
analysis	  should	  be	  carried	  out	  before	  embarking	  on	  any	  particular	  research	  in	  order	  
to	  assure	  the	  proposed	  research	  topic	  and	  technique	  are	  well	  informed	  to	  make	  the	  
most	  advantageous	  use	  of	  research	  resources	  and	  efforts.	  	  Several	  scientific	  and	  
government	  organizations	  have	  dedicated	  research	  or	  are	  pursuing	  methodologies	  
in	  this	  very	  area	  of	  gaps	  analysis	  and	  they	  include	  The	  Patient	  Centered	  Outcomes	  
Research	  Institute	  (PCORI),14	  the	  Institute	  of	  Medicine,14	  Cochrane,15	  and	  the	  U.S.	  
Food	  and	  Drug	  Administration.16	  A	  new	  and	  increasingly	  popular	  method	  intended	  
to	  facilitate	  gaps	  analysis	  is	  the	  scoping	  review.11-­‐13	  
	  
The	  objective	  of	  this	  paper	  is	  to	  detail	  future	  research	  opportunities	  in	  the	  field	  of	  
economic	  evaluation	  in	  kidney	  transplantation	  through	  a	  scoping	  review	  and	  a	  
methodologically	  driven	  gaps	  analysis.	  	  We	  believe	  this	  will	  be	  helpful	  as,	  to	  our	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knowledge,	  there	  is	  no	  study	  that	  summarizes	  the	  sum	  total	  of	  economic	  literature	  
written	  on	  kidney	  transplantation	  nor	  identifies	  current	  research	  gaps	  in	  the	  
literature	  from	  such	  a	  study.	  
	  
Methods	  
Four	  medical	  electronic	  databases	  (PubMed/MEDLINE17,	  SciVerse	  Scopus18,	  Elsevier	  
Embase19,	  and	  the	  Cochrane	  Library20)	  and	  two	  economic	  electronic	  databases	  
(EBSCO	  EconLit	  with	  Full	  Text21	  and	  the	  Center	  for	  the	  Evaluation	  of	  Value	  and	  Risk	  
in	  Health	  Cost-­‐Effectiveness	  Analysis	  Registry22)	  were	  searched	  over	  their	  entire	  
coverage	  dates	  for	  relevant	  articles	  in	  the	  English	  language.	  	  All	  searches	  were	  
performed	  to	  and	  including	  September	  13,	  2014.	  Two	  librarians	  trained	  in	  
systematic	  reviews	  assisted	  in	  creating	  and	  reviewing	  the	  search	  strategies	  
(Appendix	  1).	  Reference	  lists	  of	  review	  articles	  and	  other	  relevant	  articles	  were	  
hand-­‐searched	  to	  identify	  additional	  articles.	  
	  
All	  articles	  that	  included	  an	  economic	  evaluation	  of	  human	  kidney	  transplantation	  
were	  included.	  	  Articles	  were	  excluded	  if	  they	  did	  not	  provide	  original	  work	  (i.e.	  
reviews),	  were	  not	  in	  English	  or	  were	  not	  journal	  articles	  or	  economic	  working	  
papers	  (e.g.	  commentaries,	  theses,	  abstracts).	  	  Economic	  evaluation	  was	  defined	  as	  
dealing	  with	  costing,	  cost-­‐effectiveness,	  financial	  strategies	  or	  economic	  theories	  
and	  models.	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Two	  authors	  (TE	  and	  IH)	  reviewed	  all	  article	  titles	  and	  abstracts	  and	  retained	  only	  
those	  articles	  deemed	  eligible	  according	  to	  the	  inclusion	  and	  exclusion	  criteria	  
stated	  above.	  	  All	  articles	  were	  retained	  where	  at	  least	  one	  author	  deemed	  the	  
article	  eligible.	  	  The	  resultant	  articles	  were	  then	  subject	  to	  full	  article	  review	  for	  
final	  eligibility	  into	  the	  study.	  A	  single	  author	  (TE)	  performed	  the	  full	  text	  review	  
that	  resulted	  in	  the	  final	  number	  of	  articles	  for	  study	  analysis.	  
	  
Articles	  were	  categorized	  in	  two	  manners:	  by	  topic	  and	  by	  evaluation	  technique.	  	  
Topic	  categorization	  was	  aided	  by	  the	  development	  of	  a	  conceptual	  framework.	  	  In	  
order	  to	  account	  for	  the	  breadth	  and	  depth	  of	  literature	  sought	  in	  this	  study,	  a	  
conceptual	  framework	  was	  designed	  from	  the	  viewpoint	  of	  economic	  evaluation	  of	  
macro-­‐	  and	  micro-­‐environmental	  elements	  as	  they	  relate	  to	  kidney	  transplantation	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Overall,	  the	  Donabedian	  medical	  care	  quality	  evaluation	  model	  of	  structure,	  process	  
and	  outcome	  was	  employed	  where	  the	  structure	  component	  mirrors	  
macroeconomic	  concepts	  and	  the	  process	  component	  parallels	  microeconomic	  
concepts.23	  The	  structure	  portion	  of	  the	  conceptual	  model,	  defined	  as	  the	  
environment	  over	  which	  the	  transplant	  candidate	  or	  provider	  have	  no	  direct	  control,	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was	  further	  characterized	  according	  to	  a	  PESTLE	  analysis.24	  PESTLE	  analysis	  is	  
commonly	  used	  in	  business	  practice	  to	  evaluate	  how	  best	  to	  position	  a	  business	  
within	  its	  macro-­‐environment	  in	  terms	  of	  industry	  areas	  of	  growth	  and	  potential	  
future	  operations.	  	  The	  PESTLE	  categories	  were	  adapted	  for	  the	  purposes	  of	  this	  
study	  and	  the	  categories	  were	  defined	  as:	  1)	  Political:	  society’s	  coverage	  of	  kidney	  
transplantation,	  2)	  Economic/financial	  environment:	  qualitative	  financial	  burden	  on	  
nation	  and	  individuals,	  3)	  Socio-­‐cultural	  and	  ethical:	  society’s	  view	  and	  willingness	  
to	  participate	  in	  kidney	  transplantation	  or	  to	  allow	  a	  market	  for	  organs,	  4)	  
Technological:	  newly	  introduced	  diagnostic	  or	  treatment	  options	  including	  
screening	  protocols,	  donor	  kidney	  preservation	  techniques	  and	  new	  
immunosuppression	  or	  induction	  regimens,	  5)	  Legal:	  national	  donor	  organ	  
allocation	  practices,	  and	  6)	  Environmental:	  the	  environment	  of	  treatment	  options	  a	  
transplant	  candidate	  finds	  including	  dialysis	  and	  the	  availability,	  quality	  and	  
outcomes	  of	  donor	  organs.	  	  
	  
The	  process	  portion	  of	  the	  conceptual	  model	  deals	  with	  the	  interaction	  between	  the	  
transplant	  candidate	  (demand	  side)	  and	  their	  physician	  or	  hospital	  provider	  (supply	  
side)	  in	  terms	  of	  the	  associated	  factors	  over	  which	  they	  have	  direct	  control.	  	  The	  
outcomes	  portion	  of	  the	  model	  is	  placed	  at	  the	  center	  of	  the	  structure	  and	  process	  
macro-­‐	  and	  micro-­‐environment.	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Each	  paper	  was	  also	  then	  categorized	  according	  to	  the	  evaluation	  technique	  
employed	  which	  included	  costing,	  cost-­‐effectiveness,	  economic	  modeling	  or	  theories	  
and	  qualitative	  financial	  impact.	  	  
	  
Research	  Gaps	  Analysis	  
With	  the	  intent	  to	  describe	  research	  gaps,	  the	  guidelines	  for	  the	  analysis	  of	  
systematic	  reviews	  according	  the	  Agency	  for	  Healthcare	  Research	  and	  Quality	  
(AHRQ)25	  were	  employed	  since	  no	  research	  gaps	  methodology	  exists	  for	  scoping	  
reviews	  like	  this	  one.	  	  Along	  with	  the	  AHRQ	  suggested	  “PICOS”	  data	  abstraction	  of	  
study	  population,	  intervention,	  comparison	  group,	  outcomes,	  setting	  as	  well	  as	  
reason	  for	  any	  gap,	  additional	  data	  including	  topic	  categorization,	  evaluation	  
technique,	  year,	  title,	  author,	  journal,	  country,	  study	  time	  interval,	  study	  perspective,	  
use	  of	  Markov	  models,	  whether	  the	  year	  of	  currency	  was	  specified	  and	  whether	  any	  
of	  the	  authors	  were	  from	  industry	  (one	  rough	  marker	  for	  potential	  conflict	  of	  
interest	  bias)	  were	  recorded.	  	  Qualitative	  and	  quantitative	  data	  abstraction	  was	  
performed	  by	  one	  author	  (TE).	  	  
	  
The	  AHRQ	  uses	  an	  A-­‐D	  system	  for	  characterizing	  potential	  research	  gaps	  in	  
systematic	  reviews.	  In	  this	  manner,	  all	  the	  qualitative	  data	  can	  be	  consolidated	  into	  
four	  basic	  gaps	  categories.	  	  In	  adapting	  these	  AHRQ	  guidelines	  to	  this	  scoping	  
review,	  the	  four	  characterizations	  of	  gaps	  were	  defined	  as	  1)	  A:	  insufficient	  or	  
imprecise	  data	  taken	  to	  mean	  no	  significant	  conclusion,	  2)	  B:	  biased	  information	  
taken	  to	  mean	  single-­‐center	  studies	  with	  no	  statistically	  significant	  result	  or	  
	   	  
	   19	  
sensitivity	  analyses,	  3)	  C:	  inconsistent	  or	  unknown	  consistency	  of	  results	  taken	  to	  
mean	  any	  topic	  that	  only	  had	  one	  study	  or	  any	  group	  of	  five	  or	  less	  studies	  that	  had	  
conflicting	  conclusions,	  and	  4)	  D:	  not	  the	  right	  information	  taken	  to	  mean	  study	  
results	  with	  a	  time	  horizon	  less	  than	  5	  years	  (knowing	  that	  kidney	  donor	  organ	  
survival	  is	  still	  83%	  at	  5	  years	  and	  58%	  at	  10	  years).3	  
	  
Results	  
Total	  Number	  of	  Articles	  by	  Year,	  Topic,	  Country	  and	  Journal	  
The	  electronic	  search	  resulted	  in	  a	  total	  of	  5,507	  articles	  with	  no	  duplicates	  (Figure	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1Medical	  databases	  included	  MEDLINE,	  Scopus,	  Embase	  and	  the	  Cochrane	  Library	  
	  
2Economic	  databases	  included	  EconLit	  with	  Full	  Text	  and	  the	  Cost-­‐Effectiveness	  Analysis	  Registry	  of	  
Tufts	  University	  
	  
3These	  other	  sources	  include	  commentaries,	  editorials,	  personal	  viewpoints,	  personal	  perspectives,	  
book	  reviews,	  books,	  newspapers,	  interviews,	  theses,	  dissertations,	  abstracts,	  poster	  presentations,	  




Review	  of	  titles	  and	  abstracts	  resulted	  in	  900	  articles	  for	  full	  review.	  	  Full	  text	  
review	  produced	  the	  final	  list	  of	  278	  eligible	  articles	  (Appendix	  2)	  that	  spanned	  46	  
years,	  1968-­‐2014,	  with	  11	  years	  where	  no	  articles	  were	  identified	  (1969-­‐1975,	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1977,	  1979,	  1982,	  1984).	  	  Seventy-­‐one	  percent	  of	  the	  articles	  were	  published	  in	  
2000	  or	  later	  (Figure	  3)	  with	  the	  increase	  in	  articles	  being	  largely	  driven	  by	  the	  
evaluation	  of	  new	  medicines	  and	  technology	  as	  applied	  to	  transplantation.	  	  	  
	  
Figure	  3.	  Graph	  of	  the	  Number	  of	  Overall	  and	  Four	  Most	  Common	  Articles	  




The	  most	  common	  topics	  involved	  immunosuppressants,	  infectious	  disease	  
prophylaxis,	  dialysis	  versus	  kidney	  transplantation,	  donor	  organ	  allocation	  and	  a	  




	   	  























Even	  these	  most	  popular	  topics	  only	  averaged	  between	  0.7-­‐1.3	  articles	  per	  year	  over	  
the	  35	  years	  where	  articles	  were	  identified.	  The	  remaining	  topics	  each	  contributed	  
18	  articles	  or	  less	  over	  the	  46	  year	  time	  span.	  	  One	  hundred	  forty-­‐six	  of	  the	  articles	  
(53%)	  were	  from	  the	  United	  States	  with	  the	  next	  highest	  counts	  coming	  from	  
Canada	  (9%),	  the	  United	  Kingdom	  (6%),	  and	  Australia	  (4%)	  (Table	  2).	  	  	  
Conceptual	  framework	  heading	   Number	  of	  
articles	  in	  
category	  
TECHNOLOGICAL	   96	  (35%)	  
a.	  Immunosuppression	  medications	   46	  
b.	  Prophylaxis	   27	  
c.	  Induction	  therapy	   18	  
d.	  Laparoscopic	  donor	  nephrectomy	   5	  
ENVIRONMENTAL	   53	  (19%)	  
e.	  Dialysis	  versus	  transplantation	   43	  
f.	  Organ	  quality	   10	  
LEGAL	   31	  (11%)	  
g.	  Allocation	   31	  
SOCIO-­‐CULTURAL	  and	  ETHICAL	   25	  (9%)	  
h.	  Market	  for	  organs	   25	  
POLITICAL	   22	  (8%)	  
i.	  Coverage	  	   22	  
PROVIDER-­‐LEVEL	  FACTORS	   18	  (6%)	  
j.	  Hospital/physician	  factors	   14	  
k.	  Evaluation	  process	   3	  
l.	  Accept/reject	  decision	   1	  
PATIENT	  LEVEL	  FACTORS	   18	  (6%)	  
m.	  Living	  donors	  	   7	  
n.	  Adherence	   5	  
o.	  Quality	  of	  life	  measurements	   2	  
p.	  Financial	  strain	   2	  
q.	  Accept/reject	  decision	   2	  
Economic/Financial	  	  	   15	  (5%)	  
r.	  Economic	  considerations	   15	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Table	  2.	  	  Country	  of	  Senior	  Author	  
	  
Country	   Total	  number	  of	  
articles	  per	  
country	  
United	  States	   146	  	  
Canada	   24	  	  
United	  Kingdom	   17	  	  
Australia	   10	  
The	  Netherlands,	  Spain	   9	  	  
France	   7	  	  
Switzerland	   6	  	  
Germany	   5	  	  
Chile,	  Iran,	  Italy,	  Japan,	  Taiwan	   4	  	  
India,	  Sweden,	  Turkey	   3	  	  
Hungary	   2	  
Austria,	  Belgium,	  Bosnia	  &	  Herzegovina,	  Brazil,	  Bulgaria,	  Dominican	  
Republic,	  Greece,	  Israel,	  New	  Zealand,	  Norway,	  Poland,	  Saudi	  Arabia,	  




No	  other	  country	  contributed	  more	  than	  9	  articles	  in	  this	  analysis	  (noting	  again	  that	  
only	  articles	  written	  in	  English	  were	  included).	  	  All	  of	  the	  articles	  came	  from	  102	  
journals	  (68	  medical	  journals	  and	  34	  economic	  journals	  or	  working	  paper	  centers)	  
and	  82%	  of	  the	  articles	  were	  found	  in	  medical	  journals.	  	  	  
	  
Only	  three	  medical	  journals	  contained	  5%	  or	  more	  of	  the	  total	  articles	  
(Transplantation	  Proceedings	  16%,	  Transplantation	  10%	  and	  the	  American	  Journal	  
of	  Transplantation	  5%)	  while	  only	  six	  economic	  sources	  contained	  1%	  or	  more	  of	  
the	  total	  articles	  (The	  American	  Economic	  Review	  1%,	  Contemporary	  Economic	  
Policy	  1%,	  National	  Bureau	  of	  Economic	  Research	  Working	  Papers	  1%,	  Economic	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Inquiry	  1%,	  Journal	  of	  Economic	  Perspectives	  1%	  and	  Journal	  of	  Economic	  Theory	  
1%).	  
	  
Qualitative	  Evaluation	  of	  Studies	  with	  Identification	  of	  Gaps	  
Population	  
The	  intervention	  and	  comparison	  populations	  were	  evaluated	  based	  on	  age	  and	  
study	  size.	  The	  majority	  of	  articles,	  63%,	  did	  not	  explicitly	  state	  whether	  the	  
population	  was	  adult	  or	  pediatric	  or	  both.	  	  Thirty-­‐one	  percent	  of	  the	  articles	  
stipulated	  adult	  populations	  while	  only	  0.4%	  examined	  exclusively	  pediatric	  
populations	  and	  6%	  stated	  that	  the	  population	  was	  a	  mixed	  adult	  and	  pediatric	  
population.	  	  Study	  size	  ranged	  from	  1-­‐274,832	  with	  29%	  of	  papers	  relying	  on	  single	  
center	  populations	  and	  18%	  relying	  on	  multi-­‐center	  populations.	  	  Of	  note,	  20%	  of	  
the	  costing	  and	  cost-­‐effectiveness	  papers	  used	  Markov	  modeling	  of	  populations	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Cohort	  type	   	   	   	   	   	   	  
Prospective	   6	   26	   7	   0	   0	   14%	  
Retrospective	   45	   123	   58	   3	   10	   86%	  
*Perspective	   	   	   	   	   	   	  
Payer/Medicare/hospital/national	  
health	  insurance/society	  
47	   148	   56	   1	   3	   92%	  
Patient	   6	   7	   13	   2	  	   8	   13%	  
Age	  of	  population	   	   	   	   	   	   	  
Adults	   20	   54	   7	   0	   5	   31%	  
Pediatrics	   0	   1	   0	   0	   0	   0.4%	  
Both	  adults	  and	  pediatrics	   5	   8	   1	   0	   2	   6%	  
Not	  specified	   26	   86	   57	   3	   3	   63%	  
**Study	  size	   	   	   	   	   	   	  






0	   3	  [77-­‐129]	   29%	  






0	   3	  [254-­‐
305]	  
18%	  
Markov	  model	  (only	  including	  
costing	  and	  CEA	  papers)	  
1	   38	   N/A	   N/A	   N/A	   20%	  
One	  or	  more	  authors	  from	  
pharmaceutical	  company	  (only	  
including	  costing	  and	  CEA	  papers)	  
5	   21	   0	   0	   0	   9%	  
Year	  of	  currency	  specified	   29	   97	   N/A	   N/A	   N/A	   63%	  
***Time	  horizon	  of	  study	  (only	  
including	  costing,	  CEA	  and	  
financial	  impact	  papers)	  
	   	   	   	   	   	  
≤	  1	  year	   22	   61	   N/A	   N/A	   0	   39%	  
1-­‐5	  years	   20	   33	   N/A	   N/A	   2	   26%	  
>5-­‐10	  years	   4	   19	   N/A	   N/A	   1	   11%	  
>	  10years	   3	   37	   N/A	   N/A	   1	   19%	  
Unknown	   2	   0	   N/A	   N/A	   5	   3%	  
****Gaps	  analysis	   	   	   	   	   	   	  
A	   5	   2	   0	   0	   2	   3%	  
B	   22	   32	   5	  	   0	   5	   23%	  
C	   17	   12	   5	   0	   5	   13%	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Table	  3	  notes:	  *	  A	  number	  of	  studies	  provided	  more	  than	  one	  perspective;	  **	  When	  documenting	  
“Study	  size,”	  single	  center,	  multi-­‐center	  and	  national	  database	  studies	  were	  documented	  when	  
specifically	  mentioned	  in	  the	  article;	  ***	  Time	  horizon	  is	  how	  the	  results	  were	  reported,	  not	  
necessarily	  the	  time	  horizon	  of	  the	  model	  input	  data	  if	  used;	  ****	  A:	  insufficient	  data	  to	  produce	  
significant	  results,	  B:	  biased	  data	  use,	  C:	  unknown	  consistency	  of	  results	  due	  to	  rarity	  of	  topic,	  D:	  
insufficient	  time	  interval;	  *****	  Timeline	  of	  results	  was	  not	  applicable	  in	  65	  of	  the	  studies	  so	  the	  
denominator	  in	  this	  case	  was	  213	  instead	  of	  278	  
	  
	  
Intervention	  and	  Comparison	  Groups	  
Since	  scoping	  reviews	  cover	  such	  a	  broad	  range	  of	  experimental	  interventions,	  the	  
intervention	  and	  comparison	  groups	  were	  exclusively	  described	  by	  topic	  
categorization	  (Table	  1).	  	  Gaps	  exist	  in	  financial/economic	  environment,	  
physician/provider	  and	  patient	  factors.	  
	  
Outcomes	  and	  Timing/Time	  Horizon	  
Again,	  since	  scoping	  reviews	  deal	  with	  a	  very	  large	  variety	  of	  interventions,	  
outcomes	  were	  described	  based	  on	  evaluation	  technique,	  whether	  they	  specified	  the	  
currency	  year,	  whether	  one	  of	  the	  authors	  was	  from	  industry,	  and	  the	  time	  horizon	  
of	  the	  study	  results.	  	  The	  most	  common	  evaluation	  technique	  was	  cost-­‐effectiveness	  
with	  149	  articles,	  followed	  by	  economic	  theory/modeling	  with	  65	  articles,	  costing	  
with	  51	  articles,	  qualitative	  financial	  impact	  with	  10	  articles	  and	  systematic	  reviews	  
with	  meta-­‐analyses	  with	  3	  articles.	  	  Only	  63%	  of	  the	  costing	  and	  cost-­‐effectiveness	  
articles	  specified	  a	  currency	  year	  and	  almost	  40%	  of	  the	  same	  articles	  used	  a	  time	  
horizon	  of	  one	  year	  or	  less.	  	  Another	  26%	  used	  a	  timeline	  of	  1-­‐5	  years	  making	  it	  a	  
full	  two-­‐thirds	  of	  articles	  that	  dealt	  with	  time	  horizons	  of	  5	  years	  or	  less.	  	  Less	  than	  
10%	  of	  papers	  had	  an	  author	  from	  industry	  (Table	  3).	  	  Gaps	  exist	  in	  economic	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modeling,	  meta-­‐analyses,	  time	  horizons	  over	  5	  years,	  and	  stating	  currency	  year	  
consistently.	  	  
	  
Of	  note,	  costing	  evaluations	  did	  not	  have	  an	  “effect”	  aspect	  and	  these	  types	  of	  
articles	  included,	  for	  example,	  the	  cost	  to	  Medicare	  of	  acute	  rejection,26	  the	  cost	  to	  
hospitals	  of	  invasive	  fungal	  infections,27	  the	  difference	  in	  costs	  between	  high-­‐	  and	  
low-­‐volume	  centers,28	  and	  the	  cost	  to	  the	  hospital	  of	  a	  living	  donor	  nephrectomy.29	  
Cost-­‐effective	  evaluations	  reported	  results	  with	  both	  a	  cost	  and	  effect	  component	  
and	  included	  cost-­‐utility	  evaluations.	  	  	  
	  
Economic	  modeling	  topics	  included	  supply	  and	  demand,	  welfare	  maximization,	  
combination	  optimization,	  economies	  of	  scope,	  monopsonies,	  and	  game	  theory.	  	  The	  
three	  systematic	  review	  and	  meta-­‐analysis	  articles	  evaluated	  quality	  of	  life	  
differences	  between	  dialysis	  and	  transplantation	  patients30,31	  and	  the	  cost	  
differences	  between	  dialysis	  and	  transplantation.32	  There	  were	  ten	  qualitative	  
economic/financial	  impact	  articles	  that	  were	  distinguished	  from	  costing	  or	  cost-­‐
effectiveness	  articles	  for	  their	  non-­‐monetary/qualitative	  results	  of	  financial	  or	  
economic	  events.	  	  For	  example,	  one	  study	  was	  a	  descriptive	  survey	  of	  all	  kidney	  
transplant	  centers	  in	  the	  US	  to	  assess	  the	  association	  between	  patient	  non-­‐
adherence	  as	  related	  to	  personal	  financial	  strain	  (in	  a	  qualitative,	  not	  quantitative,	  
sense)	  that	  their	  patients	  faced33	  and	  another	  was	  the	  association	  between	  the	  
“economic	  environment”	  (as	  determined	  by	  the	  Dow	  Jones	  Industrial	  Average,	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Setting	  was	  described	  by	  cohort	  type	  and	  study	  perspective.	  	  The	  majority	  of	  studies,	  
86%,	  were	  retrospective	  and	  the	  vast	  majority,	  92%,	  did	  not	  include	  the	  patient	  
perspective	  (Table	  3).	  	  Gaps	  exist	  in	  prospective	  studies	  and	  studies	  taking	  the	  
patient	  perspective.	  
	  
Gaps	  analysis	  was	  also	  performed	  by	  a	  synthesis	  of	  the	  qualitative	  evaluation	  data	  of	  
the	  articles	  into	  categories	  A-­‐D	  as	  described	  in	  the	  Methods	  section.	  	  The	  most	  
common	  gap	  was	  insufficient	  time	  interval	  (“D”)	  which	  was	  present	  in	  44%	  of	  the	  
articles,	  followed	  by	  biased	  information	  (“B”)	  which	  was	  present	  in	  23%	  of	  the	  
articles,	  inconsistent	  results	  or	  unknown	  consistency	  (“C”)	  which	  was	  present	  in	  
13%	  of	  the	  articles	  and	  insufficient	  or	  imprecise	  data	  (“A”)	  which	  was	  present	  in	  3%	  
of	  the	  articles	  (Table	  3).	  	  	  	  	  
	  
Discussion	  
Scoping	  reviews,	  or	  scoping	  studies,	  are	  a	  relatively	  new	  approach	  to	  summarizing	  
literature	  with	  the	  first	  methodological	  framework	  advanced	  in	  2005.35	  Since	  then,	  
there	  have	  been	  a	  number	  of	  scoping	  reviews	  including	  topics	  in	  complementary	  
and	  alternative	  medicine,	  health	  system	  report	  cards,	  arts-­‐based	  health	  research	  
and	  nursing.36-­‐39	  Scoping	  reviews	  are	  usually	  carried	  out	  for	  the	  purposes	  of	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evaluating	  the	  breadth	  of	  research	  on	  a	  topic,	  determining	  if	  a	  full	  systematic	  review	  
should	  be	  pursued,	  summarizing	  research	  findings	  or	  for	  identifying	  gaps	  in	  the	  
literature.35	  Regardless	  of	  its	  ultimate	  goal,	  published	  scoping	  review	  papers	  have	  
the	  ability	  to	  reduce	  duplication	  of	  literature	  reviews	  and	  guide	  subsequent	  
research.11	  We	  believe	  this	  study	  to	  be	  the	  first	  scoping	  review	  in	  the	  economic	  
evaluation	  of	  kidney	  transplantation.	  
	  
As	  there	  is	  no	  generally	  accepted	  method	  to	  perform	  gaps	  analyses	  in	  scoping	  
reviews,	  we	  adapted	  the	  AHRQ	  guidelines	  for	  research	  gaps	  for	  systematic	  reviews	  
to	  this	  study	  in	  order	  to	  bring	  a	  level	  of	  study	  quality	  evaluation	  to	  this	  scoping	  
review	  which	  is	  normally	  not	  present	  in	  scoping	  reviews.13,35	  However,	  the	  
adaptation	  needed	  to	  broaden	  the	  summary	  gaps	  categories	  of	  A-­‐D	  for	  the	  scoping	  
review	  made	  it	  so	  the	  A-­‐D	  categories	  were	  just	  one	  more	  way	  to	  evaluate	  the	  studies	  
instead	  of	  serving	  as	  an	  all-­‐inclusive	  gaps	  summary.	  	  	  
	  
Through	  our	  study,	  we	  found	  that	  gaps	  analysis	  for	  systemic	  reviews	  was	  
inadequate	  for	  scoping	  reviews	  and	  we	  propose	  that	  scoping	  review	  gaps	  analysis	  
follow	  an	  individualized	  PICO(T)S	  (“T”	  for	  timing)	  analyses.	  	  Population	  gaps	  can	  be	  
assessed	  on	  age,	  study	  size	  and	  whether	  the	  population	  was	  mathematically	  
generated.	  Intervention	  and	  comparison	  group	  gaps	  can	  be	  assessed	  by	  conceptual	  
model	  topic	  using	  our	  Donebedian/PESTLE	  model.	  	  Outcome	  gaps	  can	  be	  assessed	  
by	  technique	  categorization,	  results	  presentation	  (e.g.	  statement	  of	  currency	  year,	  
identification	  of	  potential	  industry	  biases),	  insignificant	  conclusions	  (the	  “A”	  gap	  in	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this	  paper),	  biased	  information	  from	  a	  single	  center	  (the	  “B”	  gap	  in	  this	  paper)	  and	  
assessment	  of	  rarity	  or	  conflicting	  results	  of	  similar	  studies	  (the	  “C”	  gap	  in	  this	  
paper).	  	  Finally,	  setting	  and	  timing	  gaps	  can	  be	  assessed	  by	  cohort	  type,	  study	  
perspective,	  and	  whether	  there	  was	  an	  insufficient	  time	  horizon	  (the	  “D”	  gap	  in	  this	  
paper).	  	  	  
	  
As	  scoping	  reviews	  can	  deal	  with	  such	  a	  wide	  range	  of	  topics,	  the	  addition,	  
elimination	  or	  modification/individualization	  of	  some	  of	  the	  parameters	  will	  likely	  
be	  needed,	  but	  the	  general	  framework	  and	  parameters	  presented	  here	  should	  serve	  
across	  most,	  if	  not	  all,	  topics.	  	  Also,	  we	  believe	  that	  there	  is	  no	  “gap	  summary”	  that	  
incorporates	  all	  the	  information	  in	  the	  gaps	  analysis	  but	  that	  each	  element	  in	  the	  
PICO(T)S	  evaluation	  needs	  to	  be	  appreciated	  individually	  to	  guide	  future	  research.	  	  
As	  it	  is	  likely	  that	  no	  future	  research	  project	  will	  incorporate	  all	  research	  gaps	  
identified,	  it	  makes	  sense	  that	  each	  gap	  in	  the	  PICO(T)S	  evaluation	  be	  individually	  
identified	  instead	  of	  trying	  to	  bundle	  them	  all	  into	  one	  or	  a	  few	  “overall	  summary	  
gaps.”	  
	  
Aside	  from	  a	  proposed	  gaps	  analysis	  framework	  for	  scoping	  reviews,	  we	  feel	  that	  
another	  contribution	  of	  this	  paper	  is	  the	  construction	  of	  a	  conceptual	  framework	  
designed	  to	  account	  for	  the	  breadth	  and	  depth	  of	  literature.	  	  While	  the	  Donabedian	  
model23	  gave	  the	  model	  a	  general	  structure,	  we	  used	  the	  PESTLE	  evaluation	  
methodology24	  to	  	  provide	  a	  more	  in-­‐depth	  and	  sophisticated	  categorization	  of	  the	  
material.	  	  Aside	  from	  data	  presented	  in	  the	  Results	  section,	  there	  are	  three	  further	  
	   	  
	   31	  
items	  to	  note	  about	  the	  conceptual	  model.	  	  First,	  it	  could	  be	  argued	  that	  
improvements	  or	  advances	  in	  “Macro-­‐economic”	  topics	  could	  potentially	  have	  more	  
impact	  than	  those	  in	  the	  “Micro-­‐economics”	  topics	  since	  “Macro-­‐economics”	  topics	  
can	  increase	  the	  volume	  of	  transplants	  while	  “Micro-­‐economics”	  topics	  lead	  to	  more	  
efficient	  and	  effective	  use	  of	  resources	  for	  those	  already	  involved	  in	  transplantation.	  	  	  
	  
Second,	  the	  amount	  of	  research	  activity	  in	  a	  certain	  topic	  can	  direct	  future	  
researchers	  in	  one	  of	  two	  directions.	  	  Topics	  of	  high	  research	  traffic	  may	  represent	  
areas	  of	  current	  interest	  (encouraging	  further	  research)	  or	  areas	  that	  have	  already	  
been	  adequately	  treated	  (potential	  disincentive	  for	  future	  research).	  	  Topics	  of	  low	  
research	  traffic	  may	  represent	  areas	  were	  there	  is	  no	  current	  data	  or	  no	  political	  
will	  (potential	  disincentive	  for	  future	  research)	  or	  areas	  where	  there	  is	  an	  
opportunity	  for	  exploration	  (encouraging	  for	  further	  research).	  	  Third,	  the	  
conceptual	  framework	  may	  facilitate	  the	  visual	  connection	  between	  different	  areas	  
of	  research.	  	  For	  example,	  by	  looking	  at	  the	  model,	  it	  is	  easy	  to	  consider	  how	  the	  
advantages	  of	  markets	  for	  organs	  in	  the	  Socio-­‐cultural	  and	  Ethical	  Factors	  section	  
interact	  with	  the	  other	  elements	  of	  the	  “Macro-­‐economic”	  section,	  namely	  Political	  
and	  Legal	  Factors,	  which	  may	  then	  need	  further	  research	  or	  advocacy	  in	  terms	  of	  
market	  for	  organs.	  	  	  
	  	  
Beside	  the	  summary	  of	  the	  literature	  and	  gaps	  identification	  in	  the	  Results	  section,	  
there	  are	  a	  number	  of	  other	  items	  of	  interest	  garnered	  from	  this	  scoping	  review.	  
First,	  in	  terms	  of	  volume,	  the	  literature	  in	  this	  area	  is	  relatively	  small	  with	  only	  278	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articles	  identified	  over	  46	  years	  so	  this	  is	  a	  relatively	  young	  field	  with	  great	  room	  for	  
expansion.	  	  For	  comparison,	  a	  2004	  paper	  on	  keeping	  up	  with	  the	  medical	  literature	  
for	  primary	  care	  medicine	  estimated	  that	  7,287	  articles	  were	  published	  monthly	  just	  
in	  that	  field.40	  	  
	  
Second,	  it	  is	  notable	  that	  “Macro-­‐economic”	  topics	  that	  have	  such	  a	  large	  
opportunity	  to	  benefit	  many	  people	  have	  not	  attracted	  more	  attention.	  	  For	  example,	  
research	  in	  the	  economic	  benefit	  of	  using	  high-­‐infectious	  risk	  organs	  (an	  
Environmental	  factor)	  or	  of	  future	  markets	  in	  donor	  organs	  (a	  Socio-­‐cultural	  and	  
ethical	  Factor)	  can	  lead	  to	  more	  research	  in	  how	  Political	  or	  Legal	  Factors	  could	  be	  
influenced	  to	  possibly	  accept	  these	  economically	  beneficial	  activities.	  	  	  
	  
Third,	  with	  the	  passing	  of	  the	  Patient	  Protection	  and	  Affordable	  Care	  Act	  in	  2010	  
leading	  to	  the	  establishment	  of	  the	  Patient-­‐Centered	  Outcomes	  Research	  Institute	  
(PCORI),	  there	  will	  likely	  be	  much	  more	  emphasis	  on	  patient-­‐related	  outcomes	  and	  
preferences.	  	  This	  is	  significant	  since	  only	  13%	  of	  the	  identified	  articles	  took	  a	  
patient	  perspective	  meaning	  that	  this	  is	  plenty	  of	  room	  for	  research	  in	  patient-­‐
centered	  outcomes	  in	  kidney	  transplantation.	  	  	  
	  
Fourth,	  almost	  half	  of	  the	  articles	  did	  not	  specify	  the	  currency	  standard	  year.	  	  This	  
belies	  the	  need	  for	  more	  of	  a	  standardization	  of	  the	  literature	  in	  terms	  of	  evaluation	  
techniques	  and	  manner	  of	  reporting	  results.	  	  In	  fact,	  the	  literature	  is	  dispersed	  over	  
102	  journals	  with	  only	  three	  journals	  having	  over	  5%	  of	  all	  articles	  found	  in	  the	  last	  
	   	  
	   33	  
46	  years.	  	  There	  may	  be	  a	  benefit	  of	  condensing	  the	  literature	  to	  a	  much	  smaller	  
number	  of	  journals	  which	  in	  turn	  might	  foster	  more	  specialization	  and	  appropriate	  
guidelines.	  	  	  
	  
There	  are	  several	  limitations	  of	  this	  paper.	  	  First,	  the	  electronic	  database	  searches	  
were	  not	  likely	  to	  find	  very	  early	  papers	  on	  economics	  and	  transplantation.	  	  There	  
were	  11	  years	  where	  no	  articles	  were	  found	  and	  all	  of	  the	  missing	  years	  were	  before	  
1985.	  	  However,	  over	  70%	  of	  the	  articles	  in	  this	  study	  were	  published	  in	  2000	  or	  
later	  so	  any	  articles	  missed	  before	  1985	  may	  be	  more	  of	  historical	  significance	  
rather	  than	  analytic	  significance.	  	  Second,	  and	  related	  to	  the	  first	  limitation,	  is	  the	  
fact	  that	  58	  of	  the	  278	  articles	  (21%)	  were	  found	  by	  hand	  searching	  pertinent	  
reference	  lists	  rather	  than	  through	  the	  electronic	  search.	  	  However,	  two	  librarians	  
trained	  in	  systematic	  reviews	  deemed	  the	  searches	  appropriate	  and	  our	  search	  was	  
wide,	  resulting	  in	  7,486	  hits.	  	  It	  is	  likely	  that	  the	  tagging	  of	  topics	  in	  electronic	  
databases	  has	  changed	  over	  the	  years	  and	  that	  many	  were	  not	  tagged	  sufficiently	  to	  
show	  up	  in	  our	  search.	  	  Third,	  the	  iterative	  process,	  as	  described	  in	  the	  Arksey	  and	  
O’Malley35	  and	  Levac	  et	  al.,13	  was	  handled	  with	  two	  authors	  reviewing	  titles	  and	  
abstracts	  for	  review,	  but	  only	  by	  one	  author	  for	  full	  article	  review	  and	  data	  
abstraction.	  	  However,	  the	  broad	  scope	  of	  scoping	  reviews	  requires	  a	  practical	  
assessment	  of	  resources	  and	  time	  and	  we	  felt	  comfortable	  with	  a	  single	  author	  full	  
text	  review	  and	  abstraction	  as	  that	  single	  author	  had	  training	  in	  both	  economic	  
evaluation	  and	  medicine.	  Fourth,	  we	  used	  guidelines	  for	  systematic	  reviews	  for	  gaps	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analysis	  and	  while	  these	  guidelines	  were	  not	  optimal	  for	  scoping	  reviews,	  we	  used	  	  
them	  as	  a	  basis	  to	  provide	  suggested	  guidelines.	  
	  
In	  conclusion,	  there	  are	  a	  number	  of	  reasons	  why	  contributing	  to	  the	  economic	  
literature	  in	  kidney	  transplantation	  is	  exciting	  and	  attractive.	  	  First,	  the	  field	  is	  still	  
in	  the	  early	  stages	  although	  there	  has	  been	  a	  large	  increase	  in	  activity	  in	  recent	  
years.	  	  Second,	  there	  is	  a	  great	  opportunity	  to	  affect	  many	  end-­‐stage	  renal	  disease	  
patients	  in	  need	  of	  transplantation	  who	  carry	  a	  large	  clinical	  and	  financial	  burden.	  	  
Third,	  there	  are	  a	  large	  variety	  of	  topics	  and	  techniques	  that	  are	  available	  to	  explore	  
in	  this	  field.	  	  In	  addition,	  there	  are	  several	  large	  and	  comprehensive	  databases	  
(United	  Network	  of	  Organ	  Sharing,	  Scientific	  Registry	  of	  Transplant	  Recipients,	  and	  
United	  States	  Renal	  Data	  System)	  as	  well	  as	  the	  opportunity	  to	  perform	  quasi-­‐
experimental	  research	  due	  to	  the	  fact	  that	  transplantation	  care	  varies	  by	  surgeon,	  
hospital,	  and	  organ	  procurement	  organization	  region.	  	  In	  summary,	  studying	  kidney	  
transplantation	  through	  the	  lens	  of	  economic	  evaluation	  has	  the	  opportunity	  to	  have	  
a	  large	  impact	  in	  patient	  care	  and	  there	  are	  a	  wide	  variety	  of	  topics	  and	  techniques	  
available	  for	  clinicians	  and	  economists	  to	  team	  together	  to	  address.	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Appendix	  1.	  Boolean	  Search	  Strategies	  
	  
1.	  	  PubMed/MEDLINE	  
“Economics”	  [TIAB]	  OR	  “economic”	  [TIAB]	  OR	  “utility	  theory”	  [TIAB]	  OR	  “utility	  
theories”	  [TIAB]	  OR	  “macroeconomic	  factors”	  [TIAB]	  OR	  “microeconomic	  factors”	  
[TIAB]	  OR	  “factors,	  microeconomic”	  [TIAB]	  OR	  “compensation	  and	  redress”	  [TIAB]	  
OR	  “cost	  and	  cost	  analysis”	  [TIAB]	  OR	  “capitalism”	  [TIAB]	  OR	  “resource	  allocation”	  
[TIAB]	  OR	  “health	  care	  rationing”	  [TIAB]	  OR	  “fees	  and	  charges”	  [TIAB]	  OR	  “health	  
planning	  support”	  [TIAB]	  OR	  “insurance”	  [TIAB]	  OR	  “single-­‐payer	  system”	  [TIAB]	  
OR	  “medical	  savings	  accounts”	  [TIAB]	  OR	  “health	  care	  sector”	  [TIAB]	  OR	  “medical	  
indigency”	  [TIAB]	  	  
AND	  
“Transplants”	  [TIAB]	  OR	  “organ	  transplantation”	  [TIAB]	  OR	  “transplant”	  [TIAB]	  OR	  
“transplantation”[TIAB]	  OR	  “grafts”	  [TIAB]	  OR	  “graft”	  [TIAB]	  OR	  “tissue	  
transplants”[TIAB]	  OR	  “tissue	  transplant”	  [TIAB]	  OR	  “organ	  transplants”	  [TIAB]	  OR	  
“organ	  transplant”	  [TIAB]	  OR	  “organ	  grafts”	  [TIAB]	  OR	  “organ	  graft”	  [TIAB]	  OR	  
“tissue	  grafts”	  [TIAB]	  OR	  “tissue	  graft”	  [TIAB]	  OR	  “tissue	  transplantation”	  [TIAB]	  	  
NOT	  
("animals"[MeSH	  Terms]	  NOT	  ("humans"[MeSH	  Terms]	  AND	  "animals"[MeSH	  
Terms])	  	  
	  
*	  [TIAB]	  =	  search	  of	  title	  and	  abstract	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2.	  	  Embase	  
'economics':ab,ti	  OR	  'economic':ab,ti	  	  
AND	  
'transplants':ab,ti	  OR	  'transplant':ab,ti	  OR	  'transplantation':ab,ti	  	  
NOT	  	  
'animals':ab,ti	  OR	  'heart	  transplant':ab,ti	  OR	  'heart	  transplantation':ab,ti	  OR	  'lung	  
transplant':ab,ti	  OR	  'lung	  transplantation':ab,ti	  OR	  'pancreas	  transplant':ab,ti	  OR	  
'pancreas	  transplantation':ab,ti	  OR	  'face	  transplant':ab,ti	  OR	  'face	  
transplantation':ab,ti	  
	  
*	  ab,ti	  =	  search	  of	  abstracts	  and	  titles	  
**	  further	  search	  modification	  included	  limiting	  the	  search	  by	  un-­‐checking	  the	  radio	  
button	  for	  MEDLINE,	  un-­‐checking	  the	  radio	  button	  for	  ‘include	  sub-­‐
terms/derivatives’	  and	  checking	  the	  radio	  button	  for	  ‘major	  focus	  in	  paper’	  
	  
3.	  Scopus	  
TITLE({Economics}	  OR	  {economic})	  
ABS({Economics}	  OR	  {economic})	  	  
AND	  
TITLE({Transplants}	  OR	  {transplant}	  OR	  {transplantation})	  
ABS({Transplants}	  OR	  {transplant}	  OR	  {transplantation})	  
NOT	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TITLE({animals}	  OR	  {heart	  transplant}	  OR	  {heart	  transplantation}	  OR	  {lung	  
transplant}	  OR	  {lung	  transplantation}	  OR	  {pancreas	  transplant}	  OR	  {pancreas	  
transplantation}	  OR	  {face	  transplant}	  OR	  {face	  transplantation})	  
ABS({animals}	  OR	  {heart	  transplant}	  OR	  {heart	  transplantation}	  OR	  {lung	  
transplant}	  OR	  {lung	  transplantation}	  OR	  {pancreas	  transplant}	  OR	  {pancreas	  
transplantation}	  OR	  {face	  transplant}	  OR	  {face	  transplantation})	  
	  
*	  final	  search	  in	  order	  to	  cover	  both	  title	  and	  abstracts:	  
(((TITLE({Economics}	  OR	  {economic}))	  AND	  (TITLE({Transplants}	  OR	  
{transplant}	  OR	  {transplantation})))	  AND	  NOT	  (TITLE({animals}	  OR	  {heart	  
transplant}	  OR	  {heart	  transplantation}	  OR	  {lung	  transplant}	  OR	  {lung	  
transplantation}	  OR	  {pancreas	  transplant}	  OR	  {pancreas	  transplantation}	  OR	  
{face	  transplant}	  OR	  {face	  transplantation})))	  OR	  (((ABS({Transplants}	  OR	  
{transplant}	  OR	  {transplantation}))	  AND	  (ABS({Economics}	  OR	  {economic})))	  
AND	  NOT	  (ABS({animals}	  OR	  {heart	  transplant}	  OR	  {heart	  transplantation}	  OR	  
{lung	  transplant}	  OR	  {lung	  transplantation}	  OR	  {pancreas	  transplant}	  OR	  
{pancreas	  transplantation}	  OR	  {face	  transplant}	  OR	  {face	  transplantation})))	  
	  
4.	  	  Cochrane	  Library	  Database	  
“Transplant,”	  “transplants,”	  or	  “transplantation”;	  all	  searched	  separately	  
	  
*	  the	  search	  was	  limited	  to	  titles,	  abstracts,	  keywords,	  economic	  evaluations	  and	  
reviews	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5.	  	  EconLit	  with	  Full	  Text	  
“Transplant”	  OR	  “transplants”	  OR	  “transplantation”	  
	  
*	  the	  search	  included	  full	  texts	  of	  the	  articles	  as	  well	  as	  any	  related	  words	  
	  
6.	  The	  Cost-­‐Effectiveness	  Analysis	  Registry	  (Tufts	  University)	  	  
“Transplant,”	  “transplants,”	  “transplantation”	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Introduction:	  Due	  to	  a	  growing	  disparity	  between	  the	  number	  of	  wait	  listed	  
transplant	  candidates	  and	  available	  organs	  for	  transplant,	  here	  has	  been	  interest	  in	  
the	  utilization	  of	  donated	  kidneys	  at	  high	  risk	  for	  infectious	  disease	  transmission	  as	  
a	  means	  to	  increase	  the	  donor	  kidney	  pool.	  
	  
Objectives:	  To	  assess	  the	  cost-­‐effectiveness	  of	  five	  national	  screening	  policies	  for	  
high	  infectious	  risk	  kidneys	  in	  order	  to	  properly	  identify	  uninfected	  organs	  and	  
increase	  their	  use.	  
	  
Methods:	  A	  decision-­‐tree	  analysis	  was	  conducted	  comparing	  five	  strategies	  of	  
screening	  organ	  donors	  for	  HIV	  and	  HCV:	  the	  current	  national	  practice	  (a	  mixture	  of	  
ELISA	  Only,	  Selective	  NAT	  with	  ELISA,	  and	  Universal	  NAT	  with	  ELISA),	  ELISA	  Only,	  
Selective	  NAT	  with	  ELISA,	  Universal	  NAT	  with	  ELISA	  and	  NAT	  Only.	  	  Probabilities,	  
costs	  and	  QALYs	  were	  taken	  from	  the	  literature.	  All	  costs	  were	  reported	  in	  2015	  US	  
dollars	  and	  the	  perspective	  was	  that	  of	  the	  payer/Medicare.	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Results:	  Outside	  of	  the	  ELISA	  Only	  strategy,	  Selective	  NAT	  with	  ELISA	  was	  the	  most	  
cost-­‐effective	  screening	  strategy	  and	  was	  associated	  with	  the	  most	  number	  of	  
uninfected	  organs	  transplanted,	  the	  least	  number	  of	  uninfected	  organs	  discarded,	  
the	  most	  number	  of	  QALYs,	  the	  least	  number	  of	  discarded	  QALYs	  and	  the	  least	  
overall	  cost	  but	  all	  at	  the	  cost	  of	  transplanting	  3	  more	  infected	  organs	  per	  year	  over	  
the	  current	  national	  screening	  practice.	  Compared	  to	  the	  current	  national	  screening	  
practice,	  Selective	  NAT	  with	  ELISA	  saves	  $18,100	  per	  QALY	  gained	  and	  carries	  a	  
screening	  budget	  impact	  to	  Medicare	  of	  $1,088,336	  saved	  per	  year.	  	  
	  
Conclusions:	  The	  Selective	  NAT	  with	  ELISA	  screening	  strategy	  is	  the	  most	  viable,	  
cost-­‐effective	  national	  screening	  policy	  for	  high	  infectious	  risk	  donor	  organs.	  
National	  guidelines	  should	  be	  determined	  in	  how	  selective	  NAT	  should	  be	  applied	  to	  






There	  were	  111	  fewer	  adult	  kidney	  transplants	  in	  2011	  compared	  to	  the	  previous	  
year	  while	  the	  kidney	  transplant	  list	  grew	  4%	  in	  that	  same	  timeframe.1	  Time	  on	  the	  
waitlist	  is	  associated	  with	  increased	  mortality2-­‐8,	  decreased	  quality	  of	  life9	  and	  
disproportionately	  high	  Medicare	  charges.10	  There	  have	  been	  many	  efforts	  to	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increase	  the	  pool	  of	  organs	  including	  encouraging	  more	  living	  and	  deceased	  
donations,	  expanding	  the	  criteria	  of	  organs	  that	  are	  used,	  exploring	  a	  market	  for	  
donated	  organs	  and	  funding	  basic	  research	  in	  stem	  cells	  and	  xenotransplantation.11-­‐
15	  Another	  specific	  area	  of	  interest	  is	  in	  the	  appropriate	  utilization	  of	  donated	  
organs	  at	  high	  risk	  for	  infectious	  disease	  transmission.	  
	  
Centers	  for	  Disease	  Control	  and	  Prevention	  (CDC)	  high-­‐risk	  donors	  (HRD)	  are	  those	  
at	  higher	  risk	  for	  human	  immunodeficiency	  virus	  (HIV)	  and	  hepatitis	  C	  virus	  (HCV)	  
infection	  than	  the	  general	  population	  even	  in	  the	  face	  of	  negative	  serologic	  testing.16	  
This	  higher	  risk	  is	  conferred	  through	  nine	  behaviors	  or	  being	  on	  hemodialysis,	  as	  
defined	  by	  the	  U.S.	  Public	  Health	  Service,	  since	  blood	  testing	  may	  still	  be	  negative	  
due	  to	  the	  possibility	  of	  window	  period	  (WP)	  infections.17-­‐20	  The	  CDC	  states	  that	  
these	  organs	  should	  not	  be	  used	  except	  in	  emergent	  or	  life-­‐threatening	  instances	  
where	  the	  benefits	  outweigh	  the	  risks.19	  There	  have	  been	  at	  least	  seven	  reported	  
incidents	  of	  viral	  disease	  transmission	  from	  a	  solid	  organ	  donor	  to	  transplant	  
recipients.21-­‐23	  The	  publicity	  surrounding	  the	  transmission	  of	  infectious	  disease	  
through	  solid	  organ	  transplantation	  lead	  to	  at	  least	  a	  third	  of	  transplant	  surgeons	  to	  
change	  their	  practice	  in	  decreasing	  their	  use	  of	  HRDs.22,24,25	  One	  option	  to	  decrease	  
the	  transmission	  of	  infectious	  diseases	  would	  be	  to	  use	  nucleic	  acid	  testing	  (NAT)	  in	  
screening	  donor	  organs	  as	  it	  is	  a	  more	  sensitive	  test	  than	  the	  currently	  UNOS	  
mandated	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA).	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The	  reason	  for	  interest	  in	  HRDs	  is	  that	  they	  constitute	  approximately	  9%	  of	  donors	  
where	  at	  least	  one	  organ	  is	  recovered26	  and	  their	  actual	  risk	  of	  infection	  is	  relatively	  
low	  (ranging	  from	  0.09-­‐12.1	  per	  10,000	  donors	  based	  on	  the	  serologic	  window	  
period	  for	  HIV	  and	  from	  0.26-­‐300.6	  infections	  per	  10,000	  donors	  based	  on	  the	  
serologic	  window	  period	  for	  HCV).16,24,27	  The	  volume	  of	  uninfected	  HRDs	  that	  are	  
discarded	  each	  year	  due	  to	  their	  HRD	  status,	  if	  used,	  would	  increase	  the	  number	  of	  
uninfected	  organs	  available	  for	  transplant	  each	  year	  and	  it	  could	  be	  done	  with	  
higher	  overall	  survival	  and	  QALYs	  with	  decreased	  transmission	  of	  diseases	  (one	  
study	  has	  shown	  that	  hepatitis	  C	  transmission	  on	  hemodialysis	  can	  occur	  more	  
frequently	  than	  if	  all	  HRD	  organs	  were	  transplanted)	  and	  overall	  cost.24,28	  In	  
addition,	  outcomes	  of	  HRD	  transplants,	  in	  terms	  of	  patient	  and	  graft	  survival,	  are	  no	  
different	  when	  compared	  to	  standard	  criteria	  donor	  organs	  and	  models	  show	  their	  
benefits	  outweigh	  their	  risks.28-­‐30	  
	  
The	  main	  advantage	  of	  using	  NAT	  in	  order	  to	  better	  identify	  uninfected	  HRDs	  would	  
be	  in	  the	  increased	  willingness	  of	  transplant	  surgeons	  to	  use	  NAT	  negative	  HRDs	  
since	  NAT	  would	  likely	  only	  prevent	  a	  small	  number	  of	  potential	  serologic	  window	  
period	  infections.25	  The	  use	  of	  NAT	  in	  organ	  transplantation	  has	  not	  been	  mandated	  
as	  of	  yet20	  mostly	  due	  to	  concerns	  of	  the	  false	  positive	  rate	  (leading	  to	  an	  increase	  in	  
the	  discarding	  of	  non-­‐infected	  organs),	  cost,	  availability	  and	  length	  of	  time	  needed	  
to	  receive	  the	  results.25,31-­‐33	  This	  has	  left	  relative	  equipoise	  in	  the	  use	  of	  NAT	  with	  
only	  40-­‐50%	  of	  organ	  procurement	  organizations	  (OPOs)	  always	  performing	  NAT,	  
	   	  
	   86	  
20-­‐30%	  of	  OPOs	  never	  performing	  NAT	  and	  the	  remaining	  OPOs	  selectively	  
performing	  NAT.33,34	  	  
	  
The	  objective	  of	  this	  study	  was	  to	  determine	  the	  cost-­‐effectiveness	  of	  five	  different	  
national	  donor	  organ	  screening	  strategies,	  with	  and	  without	  the	  use	  of	  NAT,	  in	  
providing	  the	  most	  number	  of	  uninfected	  kidney	  transplants,	  the	  least	  number	  of	  
infected	  kidney	  transplants	  and	  the	  least	  number	  of	  discarded	  uninfected	  organs	  at	  
an	  acceptable	  cost-­‐effective	  ratio	  of	  cost	  per	  QALY.	  	  The	  significance	  of	  establishing	  
the	  most	  efficient	  use	  of	  NAT	  testing	  would	  be	  to	  increase	  the	  deceased	  donor	  pool	  
and	  decrease	  those	  on	  the	  waiting	  list	  with	  the	  concomitant	  increase	  in	  transplant	  




A	  decision-­‐tree	  (Figure	  4)	  was	  constructed	  using	  TreeAge	  software	  (version	  2014;	  
TreeAge	  Software,	  Inc.,	  Williamstown,	  MA,	  USA).	  	  The	  decision	  tree	  compared	  five	  
strategies	  of	  screening	  organ	  donors	  for	  HIV	  and	  HCV:	  current	  national	  practice	  (a	  
mixture	  of	  ELISA	  only,	  selective	  use	  of	  NAT	  with	  ELISA,	  and	  universal	  NAT	  with	  
ELISA),	  ELISA	  only,	  selective	  use	  of	  NAT	  with	  ELISA,	  universal	  NAT	  with	  ELISA	  and	  
NAT	  only	  (no	  ELISA).	  	  The	  model	  unit	  was	  a	  one-­‐year	  amount	  of	  recovered	  kidneys,	  
taken	  to	  be	  15,449	  in	  this	  model	  based	  on	  the	  OPTN	  website	  for	  recovered	  kidneys	  
in	  2014.35	  While	  15,449	  kidneys	  were	  recovered,	  they	  came	  from	  only	  7,763	  
deceased	  donors	  meaning	  each	  donor	  contributed	  1.99	  kidneys.	  	  For	  this	  reason,	  the	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cost	  of	  screening	  was	  based	  on	  half	  of	  the	  15,449	  kidneys	  rather	  than	  the	  full	  15,449.	  
This	  model	  was	  taken	  from	  a	  payer/Medicare	  perspective.	  
	  
Figure	  4	  –	  Decision	  Tree.	  The	  NAT	  Only	  sub-­‐tree	  is	  displayed.
	  
Probabilities	  
A	  literature	  search	  was	  conducted	  to	  define	  chance	  node	  probabilities.	  	  Of	  note,	  the	  
prevalence	  of	  pre-­‐window	  period	  infections,	  window	  period	  infections	  and	  
uninfected	  individuals	  among	  both	  high-­‐	  and	  low-­‐risk	  donors	  were	  taken	  as	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“knowns”	  in	  this	  model	  as	  determined	  by	  the	  literature	  search.	  	  This	  approach	  
allowed	  the	  use	  of	  screening	  test	  sensitivities	  and	  specificities	  while	  ranging	  the	  
prevalence	  of	  infection	  over	  their	  confidence	  intervals.	  	  Decision	  tree	  probabilities,	  
















Table	  4	  –Decision	  Tree	  Probabilities,	  Costs,	  QALYs	  and	  Life	  Expectancies	  
Probabilities	   Value	  (range)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
References	  
Universal	  NAT	   0.584	  (0.466-­‐0.684)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  33,34,36	  
Selective	  NAT	   0.243	  (0.207-­‐0.310)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  33,34,36	  
ELISA	  Only	  (never	  NAT)	   0.173	  (0.036-­‐0.310)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  33,34,36	  
	   	   	  
High-­‐risk	  organs	  recovered	   0.088	  (0.023-­‐0.261)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  24,33	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Average-­‐risk	  organs	  recovered	   0.912	  (0.739-­‐0.977)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  24,33	  
	   	   	  
NAT	  available	  for	  transplant	  decision	   0.482	  (0.364-­‐0.632)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  33,36	  
NAT	  unavailable	  for	  transplant	  decision	   0.518	  (0.368-­‐0.636)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  33,36	  
	   	   	  
High-­‐risk	  organs	  infected	  pre-­‐window	  
period	   0.186	  (0.159-­‐0.215)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  37	  
High-­‐risk	  organ	  infected	  in	  NAT	  window	  
period	   0.000335911	  (0.00030261-­‐0.00037527)	  	  	  	  	  	  	  	  	  	  	  	  16,27,38	  
High-­‐risk	  organ	  uninfected	  (using	  NAT	  
window	  period)	   0.813664089	  (0.78417473-­‐0.84112239)	  	  	  	  	  	  	  	  	  	  	  	  16,27,38	  
High-­‐risk	  organ	  infected	  in	  ELISA	  window	  
period	   0.002871893	  (0.00260615-­‐0.00318866)	  	  	  	  	  	  	  	  	  	  	  	  16,27,38	  
High-­‐risk	  organ	  uninfected	  (using	  ELISA	  
window	  period)	   0.811128107	  (0.78136134-­‐0.83881885)	  	  	  	  	  	  	  	  	  	  	  	  16,27,38	  
	   	   	  
Average-­‐risk	  organ	  infected	  pre-­‐window	  
period	   0.0352	  (0.0314-­‐0.0397)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  37	  
Average-­‐risk	  organ	  infected	  in	  NAT	  window	  
period	   0.000023997875	  (0.000012409-­‐0.000042566)	  37	  
Average-­‐risk	  organ	  uninfected	  (using	  NAT	  
window	  period)	   0.964776002125	  (0.96025743-­‐0.96853759)	  	  	  	  	  	  37	  
Average-­‐risk	  organ	  infected	  in	  ELISA	  
window	  period	   0.0002125025	  (0.00011257-­‐0.00035273)	  	  	  	  	  	  	  	  	  	  	  37	  
Average-­‐risk	  organ	  uninfected	  (using	  ELISA	  
window	  period)	   0.9645874975	  (0.95994727-­‐0.96843743)	  	  	  	  	  	  	  	  	  	  	  37	  
	   	   	  
NAT	  sensitivity	   0.99	  (0.911-­‐1)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  39,40	  
NAT	  specificity	   0.9685	  (0.94-­‐1)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  39,40	  
NAT	  false	  positive	   0.0315	  (0-­‐0.06)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  39,40	  
NAT	  false	  negative	   0.01	  (0-­‐0.089)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  39,40	  
NAT	  positive	  in	  NAT	  window	  period	  
infection	   0	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
NAT	  negative	  in	  NAT	  window	  period	  
infection	   1	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
	   	   	  
ELISA	  sensitivity	   0.979	  (0.929-­‐1)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  41,42	  
ELISA	  specificity	   0.9992	  (0.9695-­‐1)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  41,42	  
ELISA	  false	  positive	   0.0008	  (0-­‐0.0305)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  41,42	  
ELISA	  false	  negative	   0.021	  (0-­‐0.071)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  41,42	  
ELISA	  positive	  in	  window	  period	  infection	   0	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
ELISA	  negative	  in	  window	  period	  infection	   1	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
	   	   	  
NAT	  and	  ELISA	  combined	  sensitivity	   0.99	  (0.911-­‐1)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  39-­‐42	  
NAT	  and	  ELISA	  combined	  specificity	   0.9685	  (0.94-­‐1)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  39-­‐42	  
NAT	  and	  ELISA	  combined	  false	  positive	   0.0315	  (0-­‐0.06)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  39-­‐42	  
NAT	  and	  ELISA	  combined	  false	  negative	   0.01	  (0-­‐0.089)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  39-­‐42	  
NAT	  and	  ELISA	  combined	  positive	  in	  NAT	  
window	  period	  infection	   0	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
NAT	  and	  ELISA	  negative	  in	  NAT	  window	  
period	  infection	   1	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
	   	   	  
Use	  high-­‐risk	  NAT	  negative	  organ	   0.875	  (0.781-­‐0.987)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  25,37	  
Discard	  high-­‐risk	  NAT	  negative	  organ	   0.125	  (0.013-­‐0.219)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  25,37	  
	   	  
	   90	  
Use	  high-­‐risk	  ELISA	  negative	  organ	   0.848	  (0.703-­‐0.954)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  25,37	  
Discard	  high-­‐risk	  ELISA	  negative	  organ	   0.152	  (0.046-­‐0.297)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  25,37	  
	   	   	  
Use	  average-­‐risk	  NAT	  negative	  organ	   1	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
Discard	  average-­‐risk	  NAT	  negative	  organ	   0	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
Use	  average-­‐risk	  ELISA	  negative	  organ	   1	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
Discard	  average-­‐risk	  ELISA	  negative	  organ	   0	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
	   	   	  
Use	  high-­‐risk	  NAT	  and	  	  ELISA	  negative	  
organ	   0.875	  (0.781-­‐0.987)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  25,37	  
Discard	  high-­‐risk	  NAT	  and	  ELISA	  negative	  
organ	   0.125	  (0.013-­‐0.219)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  25,37	  
Use	  average-­‐risk	  NAT	  and	  ELISA	  negative	  
organ	   1	  (N/A)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
Discard	  average-­‐risk	  NAT	  and	  ELISA	  
negative	  organ	   0	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
Use	  of	  any	  organ	  that	  iis	  NAT	  and/or	  ELISA	  
positive	   0	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
Discard	  any	  organ	  that	  is	  NAT	  and/or	  ELISA	  
positive	   1	  (N/A)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  N/A	  
	   	   	  
Costs	   	   	  
Nucleic	  acid	  testing	   $893	  ($32-­‐$9,662)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  36	  
Dialysis	  (lifetime)	   $750,313	  ($481,252-­‐$1,039,155)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  
Transplantation	  (lifetime)	   $638,947	  ($393,830-­‐$923,105)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  
Living	  with	  HIV	  and/or	  HCV	  (lifetime)	   $218,101	  ($164,182-­‐$505,086)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  43,44	  
	   	   	  
QALYs	  (lifetime)	   	   	  
True	  positive	  (dialysis)	   5.2	  (3.1-­‐7.8)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  45	  	  	  	  
False	  positive	  (dialysis)	   5.2	  (3.1-­‐7.8)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  45	  
True	  negative	  (transplant	  with	  uninfected	  
organ)	   12.3	  (7.4-­‐18)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  45	  
False	  negative	  (transplant	  with	  infected	  
organ)	   11	  (5.2-­‐17.6)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  45-­‐47	  
	   	   	  
Life	  expectancy	   	   	  
Dialysis	   7.5	  (5-­‐10)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2,48-­‐50	  
Transplantation	   15	  (10-­‐20)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2,48-­‐50	  





The	  decision	  tree	  analysis	  took	  the	  perspective	  of	  the	  payer	  (i.e.	  Medicare).	  	  Only	  
direct	  costs	  that	  would	  be	  affected	  by	  the	  screening	  strategy	  were	  included	  and	  
those	  were	  the	  cost	  of	  the	  screening	  strategies,	  the	  cost	  of	  transplantation	  and	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dialysis,	  and	  the	  cost	  of	  transplanting	  infected	  organs	  into	  recipients	  that	  then	  lived	  
with	  a	  transplant	  and	  HIV	  and/or	  HCV.	  ELISA	  was	  taken	  to	  cost	  $0	  as	  ELISA	  is	  
mandated	  for	  all	  donors	  and	  served	  as	  a	  baseline.	  The	  cost	  of	  living	  with	  HIV	  and/or	  
HCV	  contracted	  from	  a	  transplanted	  organ	  was	  set	  to	  the	  lifetime	  cost	  of	  
transplantation	  plus	  the	  lifetime	  cost	  of	  living	  with	  HIV	  and/or	  HCV.	  All	  costs	  were	  
converted	  to	  2015	  US$	  using	  a	  3%	  inflation	  rate.	  
	  
Outcomes	  
QALYs	  were	  calculated	  by	  multiplying	  yearly	  utility	  values	  of	  dialysis,	  kidney	  
transplantation	  and	  a	  combination	  of	  kidney	  transplantation	  with	  living	  with	  HIV	  
and/or	  HCV	  by	  the	  estimated	  life	  expectancy	  of	  those	  on	  dialysis	  or	  undergoing	  
kidney	  transplantation.	  Of	  note,	  for	  those	  who	  contracted	  HIV	  or	  HCV	  from	  a	  kidney	  
transplantation,	  we	  did	  not	  factor	  decreased	  survival	  due	  to	  the	  HIV	  and	  HCV	  
infection	  because	  the	  natural	  history	  of	  HIV	  and	  HCV	  infection	  lead	  to	  a	  longer	  life	  
span	  than	  those	  on	  dialysis	  or	  with	  a	  kidney	  transplantation.51,52	  	  
	  
QALY	  values	  for	  HIV	  infection	  were	  averaged	  from	  QALYs	  associated	  with	  people	  
with	  asymptomatic	  HIV	  infection	  (in	  the	  first	  year	  and	  subsequent	  years),	  untreated	  
and	  symptomatic	  HIV,	  highly	  active	  antiretroviral	  therapy	  (HAART)	  treatment,	  and	  
AIDS.46	  QALY	  values	  for	  HCV	  infection	  were	  averaged	  from	  QALYs	  associated	  with	  
people	  with	  mild/moderate	  chronic	  HCV,	  compensated	  cirrhosis,	  and	  
decompensated	  cirrhosis.47	  These	  averaged	  QALYs	  of	  living	  with	  HIV	  and	  HCV	  
infection	  were	  then	  multiplied	  by	  the	  life	  expectancy	  of	  a	  kidney	  transplant	  patient	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and	  were	  used	  as	  the	  QALYs	  associated	  with	  lifelong	  infection	  due	  to	  
transplantation.	  	  While	  the	  QALYs	  of	  transplantation	  were	  not	  factored	  into	  those	  
QALYs	  associated	  with	  patients	  infected	  from	  a	  transplant,	  the	  range	  of	  QALYs	  for	  
these	  individuals	  were	  broad	  enough	  that	  they	  encompassed	  any	  effect	  of	  QALYs	  
that	  transplantation	  would	  provide.	  QALYs	  were	  not	  discounted	  in	  this	  model.	  
	  
Sensitivity	  Analyses	  
Deterministic	  one-­‐way	  and	  multi-­‐way	  sensitivity	  analyses	  were	  performed.	  
Analyses	  were	  carried	  out	  in	  TreeAge	  (version	  2014;	  TreeAge	  Software,	  Inc.,	  
Williamstown,	  MA,	  USA).	  
	  
Results	  
In	  terms	  of	  total	  cost,	  the	  least	  cost-­‐effective	  strategy	  (NAT	  Only)	  cost	  $649,155	  per	  
organ	  recovered	  over	  the	  individual’s	  lifetime	  and	  the	  most	  cost-­‐effective	  strategy	  
(ELISA	  Only)	  cost	  $645,833	  per	  organ	  recovered	  making	  a	  difference	  of	  $3,322	  per	  
organ	  recovered.	  While	  the	  cost	  of	  screening	  is	  $6.9	  million	  more	  for	  the	  NAT	  Only	  
strategy,	  this	  amount	  only	  constitutes	  0.07%	  of	  the	  total	  cost	  over	  an	  individual’s	  
lifetime	  as	  the	  big	  drivers	  of	  cost	  are	  the	  use	  or	  discarding	  of	  organs	  that	  leads	  to	  
dialysis	  or	  transplantation.	  	  The	  differential	  sensitivity	  and	  specificity	  of	  ELISA	  
versus	  NAT	  as	  well	  as	  the	  potentially	  increased	  use	  of	  high-­‐risk	  NAT	  negative	  
donors	  does	  not	  make	  a	  large	  difference	  in	  overall	  costs	  per	  organ	  recovered.	  
Table	  5	  below	  presents	  the	  breakdown	  of	  costs	  of	  the	  five	  screening	  strategies	  and	  
Table	  6	  below	  shows	  the	  total	  QALYs	  associated	  with	  each	  screening	  strategy.	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Table	  5.	  Cost	  Breakdown	  Between	  the	  Five	  Screening	  Strategies	  
	  






Table	  6	  -­‐	  QALYs	  Associated	  with	  Each	  Screening	  Strategy	  
	  	  	  	  	  	  Strategy	  	  
	  
Cost	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
NAT	  Only	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  using	  
false	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  Strategy	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
QALYs	  








































The	  screening	  strategy	  with	  the	  lowest	  effectiveness	  (NAT	  Only)	  is	  associated	  with	  
173,547	  QALYs	  over	  the	  individuals’	  lifetime	  and	  the	  most	  effective	  (ELISA	  Only)	  is	  
associated	  with	  178,756	  QALYs.	  	  The	  difference	  in	  QALYs	  is	  5,209	  (for	  the	  15,449	  
recovered	  organs	  per	  year	  over	  the	  course	  of	  the	  patients’	  lifetime)	  which	  is	  the	  
lifetime	  QALYs	  associated	  with	  423	  transplanted	  waiting	  list	  candidates.	  	  
	  
Another	  matter	  to	  consider	  is	  the	  loss	  of	  QALYs	  associated	  with	  the	  false	  positives	  
(the	  difference	  in	  QALYs	  between	  transplantation	  and	  dialysis).	  	  In	  order	  to	  give	  a	  
full	  accounting	  of	  each	  strategy’s	  misclassification,	  the	  false	  negatives	  need	  to	  be	  
evaluated	  as	  well	  (Table	  7).	  	  The	  loss	  of	  QALYs	  associated	  with	  false	  positives	  were	  
calculated	  by	  multiplying	  the	  absolute	  number	  of	  false	  positives	  per	  year	  based	  on	  
15,449	  organs	  recovered	  and	  then	  multiplying	  by	  the	  difference	  in	  QALYs	  between	  
dialysis	  and	  transplantation.	  Of	  note,	  even	  using	  false	  negative	  organs	  and	  
transmitting	  HIV	  and/or	  HCV	  resulted	  in	  higher	  QALYs	  than	  remaining	  on	  dialysis.	  
	  
Table	  7	  -­‐	  False	  Positive	  and	  False	  Negative	  Counts	  by	  Screening	  Strategy	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  Strategy	  
	  
QALYs	  














































The	  NAT	  Only	  strategy	  lost	  the	  most	  number	  of	  QALYs	  while	  the	  ELISA	  Only	  strategy	  
actually	  gains	  QALYs	  as	  there	  are	  more	  QALYs	  associated	  with	  its	  false	  negative	  rate	  
than	  false	  positive	  rate.	  	  	  
	  
Cost-­‐Effectiveness	  
The	  strategy	  of	  using	  ELISA	  Only	  as	  a	  screening	  tool	  for	  CDC	  HRDs	  is	  the	  most	  cost-­‐
effective	  strategy	  and	  dominates	  all	  other	  strategies	  (meaning	  every	  other	  strategy	  
is	  more	  expensive	  and	  produces	  less	  QALYs)	  (Figure	  5).	  The	  ELISA	  Only	  strategy	  
had	  the	  advantage	  of	  having	  a	  $0	  cost	  associated	  with	  it	  since	  ELISA	  is	  required	  of	  all	  
recovered	  organs	  for	  transplantation	  and	  did	  not	  represent	  an	  incremental	  increase	  
in	  cost	  for	  any	  of	  the	  strategies	  and	  was	  therefore	  set	  as	  the	  baseline.	  When	  using	  
the	  Current	  Practice	  strategy	  as	  a	  point	  of	  reference,	  it	  can	  bee	  seen	  that	  employing	  
a	  Selective	  NAT	  with	  ELISA	  strategy	  moves	  in	  a	  more	  cost-­‐effective	  direction	  rather	  
than	  the	  Universal	  NAT	  with	  ELISA	  or	  NAT	  Only	  strategy.	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The	  cost	  per	  QALY	  of	  the	  strategies	  varied	  from	  $55,816	  (ELISA	  Only)	  to	  $57,787	  
(NAT	  Only)	  and	  all	  were	  close	  to	  the	  Current	  Practice	  screening	  strategy	  cost	  (and	  
presumably	  willingness	  to	  pay)	  of	  $56,358.	  	  These	  values	  fall	  very	  close	  to	  the	  
historic	  and	  still	  popular	  willingness	  to	  pay	  threshold	  of	  $50,000/QALY	  although	  
that	  value	  is	  outdated	  and	  of	  dubious	  origin.53	  The	  cost-­‐effectiveness	  of	  the	  
screening	  strategies	  were	  also	  close	  to	  cost-­‐effectiveness	  values	  for	  kidney	  
transplantation	  in	  the	  literature	  ($17,000-­‐$60,00015,54,55).	  
	  
	  
Figure	  5.	  	  Cost-­‐effectiveness	  of	  Five	  Screening	  Strategies	  for	  Infectious	  Risk	  in	  





Incremental	  cost-­‐effectiveness	  ratios	  (ICERs;	  the	  difference	  in	  cost	  between	  two	  
strategies	  divided	  by	  the	  difference	  in	  QALYs)	  with	  the	  ELISA	  Only	  as	  the	  baseline	  as	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well	  as	  another	  set	  of	  ICERs	  using	  Current	  Practice	  as	  the	  baseline	  are	  shown	  in	  
Table	  8	  below.	  All	  costs	  and	  QALYs	  were	  totals	  over	  the	  individual’s	  lifetime.	  
	  
Table	  8	  -­‐	  Calculation	  of	  ICERs	  Using	  ELISA	  Only	  and	  Current	  Practice	  as	  
Reference	  Strategies	  

























































ICER	   -­‐$15,815	  
	  





























ICER	   -­‐$16,171	   -­‐$14,946	   -­‐$16,950	   -­‐$22,889	   -­‐	  
	  
	  
With	  ELISA	  Only	  as	  the	  reference	  strategy,	  the	  Universal	  NAT	  with	  ELISA	  has	  the	  
largest	  magnitude	  ICER	  at	  -­‐$18,100,	  meaning	  that	  the	  strategy	  costs	  $18,100	  to	  lose	  
every	  QALY	  less	  than	  the	  QALYs	  associated	  with	  the	  ELISA	  Only	  strategy.	  	  Of	  note,	  
the	  Current	  Practice	  has	  an	  ICER	  of	  -­‐$14,946	  meaning	  that	  Medicare	  currently	  pays	  
$14,942.69	  to	  lose	  every	  QALY	  when	  compared	  to	  an	  ELISA	  Only	  screening	  strategy.	  	  
With	  ELISA	  Only	  as	  the	  baseline,	  every	  other	  strategy	  pays	  to	  lose	  QALYs.	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With	  the	  Current	  Practice	  as	  the	  baseline,	  the	  NAT	  Only	  and	  Universal	  NAT	  with	  
ELISA	  strategies	  pay	  to	  lose	  QALYs	  while	  the	  ELISA	  Only	  and	  Selective	  NAT	  with	  
ELISA	  strategies	  cost	  less	  money	  to	  gain	  QALYs.	  	  So	  while	  ELISA	  Only	  is	  a	  dominant	  
strategy	  in	  this	  study,	  if	  one	  assumes	  that	  NAT	  will	  inevitably	  be	  used	  (making	  the	  
ELISA	  Only	  strategy	  a	  non-­‐viable	  strategy)	  and	  uses	  the	  Current	  Practice	  as	  the	  
baseline	  in	  the	  ICERs,	  then	  it	  is	  clear	  that	  moving	  away	  from	  the	  Current	  Practice	  
and	  toward	  Selective	  NAT	  with	  ELISA	  would	  be	  the	  most	  cost-­‐effective	  choice.	  
	  
False	  Positives	  and	  False	  Negatives	  
Both	  NAT	  and	  ELISA	  are	  associated	  with	  false	  positive	  and	  false	  negative	  rates	  and	  
their	  differential	  number	  of	  each	  affects	  both	  costs	  and	  QALYs.	  Since	  the	  false	  
positive	  rate	  of	  NAT	  is	  of	  concern,	  Table	  9	  below	  reports	  the	  differential	  number	  of	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Table	  9	  -­‐	  Test	  Performance.	  Number	  of	  True	  Negatives,	  True	  Positives,	  False	  
Positives	  and	  False	  Negatives	  by	  Screening	  Strategy	  (Organs	  Used	  or	  Discarded	  
Based	  on	  Test	  Result	  of	  the	  Screening	  Tool)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  Strategy	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Number	  	  
and	  type	  of	  	  
organs	  



































































False	  negatives	   8	   22	   20	   16	   17	  
WP	  use	   1	   6	   5	   4	   4	  
WP	  discard	   0.1	   0.6	   0.3	   0.3	   0.4	  
Use	   7	   15	   14	   11	   12	  
Discard	   0.3	   0.8	   0.6	   0.6	   0.6	  
Total	  organs	  
used	  
14,110	   14,535	   14,535	   14,331	   14,415	  
Total	  organs	  
discarded	  
1,338	   913	   914	   1,118	   1,033	  
*	  WP	  =	  window	  period	  
	  
When	  comparing	  the	  NAT	  Only	  and	  ELISA	  Only	  strategies,	  the	  major	  differences	  in	  
organ	  usage	  comes	  in	  the	  largest	  false	  positive	  sum	  of	  organs	  of	  the	  NAT	  Only	  
strategy	  leading	  to	  discarding	  uninfected	  organs	  with	  an	  associated	  loss	  of	  QALYs	  
(NAT	  discards	  just	  over	  450	  more	  uninfected	  organs	  than	  ELISA	  Only,	  which	  has	  the	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lowest	  numbers	  of	  false	  positives).	  The	  450	  extra	  uninfected	  organs	  that	  are	  
discarded	  when	  using	  a	  NAT	  Only	  as	  compared	  to	  ELISA	  Only	  strategy	  has	  a	  
monetary	  cost	  equal	  to	  the	  number	  of	  discarded,	  uninfected	  organs	  times	  the	  
difference	  in	  lifetime	  dialysis	  cost	  and	  lifetime	  transplantation	  cost,	  or	  $50,114,700.	  
	  
The	  other	  area	  of	  large	  discrepancy	  is	  the	  false	  negative	  rate	  which	  leads	  the	  NAT	  
Only	  strategy	  to	  transplant	  the	  lowest	  number	  of	  infected	  organs	  out	  of	  the	  five	  
screening	  strategies	  and	  ELISA	  Only	  to	  transplant	  the	  largest	  number	  of	  infected	  
organs	  out	  of	  the	  five	  screening	  strategies	  (ELISA	  Only	  will	  transplant	  14	  more	  
infected	  organs	  than	  NAT	  Only	  per	  year	  assuming	  15,449	  recovered	  kidneys).	  The	  
incremental	  cost	  associated	  with	  the	  14	  extra	  infected	  organ	  transplants	  under	  the	  
ELISA	  Only	  strategy	  has	  a	  monetary	  cost	  equal	  to	  the	  number	  of	  excess	  false	  
negatives	  (14)	  times	  the	  difference	  in	  lifetime	  dialysis	  cost	  and	  lifetime	  
transplantation	  with	  contracted	  HIV	  and/or	  HCV,	  or	  $1,494,290.	  False	  positives	  
carry	  33.5	  times	  more	  of	  a	  monetary	  penalty	  than	  false	  negatives.	  
	  
Sensitivity	  Analyses	  
One-­‐way	  sensitivity	  analyses	  of	  the	  twenty	  most	  important	  variables	  revealed	  no	  
change	  in	  the	  order	  of	  cost-­‐effectiveness	  of	  the	  five	  strategies	  except	  for	  ELISA	  Only	  
dominance	  changing	  to	  Selective	  NAT	  with	  ELISA	  dominance	  when	  NAT	  specificity	  
was	  99.4%	  or	  higher	  as	  well	  as	  for	  ELISA	  specificity	  less	  than	  97.3%.	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A	  tornado	  diagram	  of	  net	  monetary	  benefits	  is	  shown	  in	  Figure	  6	  below	  
demonstrating	  the	  five	  most	  influential	  variables	  in	  determining	  comparative	  
strategy	  cost-­‐effectiveness.	  The	  QALYs	  associated	  with	  uninfected	  organ	  
transplantation	  and	  the	  lifetime	  cost	  of	  transplantation	  were	  the	  most	  influential	  
variables	  in	  determining	  which	  screening	  strategy	  was	  most	  cost-­‐effective.	  Of	  note,	  
the	  variables	  dealing	  with	  the	  concerns	  for	  NAT	  of	  availability	  and	  cost	  were	  not	  
important	  while	  the	  false	  positive	  rate	  (reflected	  as	  false	  positive	  rate	  of	  ELISA	  in	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Figure	  6	  -­‐	  Tornado	  Diagram	  of	  the	  Five	  Most	  Influential	  Variables.	  The	  solid	  
vertical	  bar	  in	  the	  “Probability	  of	  ELISA	  positive	  in	  uninfected	  organs”	  (false	  positive	  





Two-­‐way	  sensitivity	  analyses	  were	  conducted	  for	  the	  four	  parameters	  of	  most	  
interest	  with	  NAT	  testing,	  namely	  the	  cost,	  availability,	  and	  specificity	  (false	  positive	  
rate)	  of	  NAT	  as	  well	  as	  the	  use	  of	  NAT	  negative	  organs.	  	  In	  all	  these	  combinations,	  
ELISA	  Only	  remained	  the	  dominant	  strategy	  except	  when	  Selective	  NAT	  with	  ELISA	  
became	  dominant	  in	  the	  instances	  where	  NAT	  specificity	  was	  at	  or	  above	  99.4%	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when	  comparing	  the	  use	  of	  NAT	  negative	  organs	  and	  cost	  of	  NAT	  (when	  the	  cost	  of	  
NAT	  was	  somewhere	  between	  $16	  and	  $1300).	  Also,	  the	  NAT	  Only	  strategy	  became	  
dominant	  over	  the	  ELISA	  Only	  strategy	  when	  comparing	  NAT	  specificity	  with	  NAT	  
availability	  when	  NAT	  specificity	  was	  at	  99.4%	  or	  higher.	  Figure	  7	  shows	  the	  multi-­‐
way	  sensitivity	  analysis	  between	  the	  NAT	  false	  positive	  rate	  and	  the	  use	  of	  NAT	  
negative	  organs.	  
	  
Figure	  7	  –	  Two-­‐Way	  Sensitivity	  Analysis:	  Probability	  of	  NAT	  or	  ELISA	  False	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Discussion	  
When	  considering	  the	  ELISA	  Only	  strategy	  a	  non-­‐viable	  option	  in	  terms	  of	  screening	  
alternatives	  due	  to	  the	  very	  unlikely	  occurrence	  of	  all	  OPOs	  ceasing	  to	  use	  NAT	  as	  a	  
screening	  tool,	  Selective	  NAT	  with	  ELISA	  is	  the	  most	  cost-­‐effective	  screening	  
strategy	  of	  the	  remaining	  four	  strategies.	  	  The	  more	  NAT	  is	  implemented	  (i.e.	  
Universal	  NAT	  with	  ELISA	  and	  NAT	  Only	  strategies),	  the	  less	  cost-­‐effective	  the	  
screening	  strategy	  becomes	  due	  to	  increased	  cost	  and	  decreased	  QALYs.	  	  
	  
The	  cost-­‐effectiveness	  ratio	  of	  the	  Selective	  NAT	  with	  ELISA	  strategy	  is	  $55,820	  
which	  is	  comparable	  with	  a	  prior	  study	  of	  the	  effect	  of	  strategies	  accepting	  or	  
discarding	  all	  HRDs.28	  Compared	  to	  the	  Current	  Practice,	  Selective	  NAT	  with	  ELISA	  
has	  the	  most	  favorable	  ICER	  at	  a	  cost	  savings	  of	  $16,950	  for	  every	  QALY	  gained	  over	  
the	  Current	  Practice.	  While	  both	  Universal	  NAT	  with	  ELISA	  and	  NAT	  Only	  strategies	  
have	  negative	  ICERs	  as	  well,	  their	  ICERs	  are	  the	  result	  of	  increased	  cost	  for	  less	  
QALYs.	  While	  Selective	  NAT	  with	  ELISA	  has	  a	  budget	  impact	  in	  terms	  of	  paying	  for	  
NAT	  that	  is	  11	  times	  less	  than	  Universal	  NAT	  with	  ELISA	  or	  NAT	  Only,	  the	  cost	  of	  
paying	  for	  the	  NAT	  tests	  only	  accounts	  for	  0.07%	  of	  the	  total	  cost	  of	  the	  overall	  
strategies	  and	  does	  not	  change	  the	  overall	  costs	  more	  than	  $3,322	  per	  organ	  
recovered.	  	  
	  
An	  advantage	  of	  the	  Selective	  NAT	  with	  ELISA	  strategy	  over	  the	  Universal	  NAT	  with	  
ELISA	  or	  NAT	  Only	  strategy	  is	  that	  Selective	  NAT	  with	  ELISA	  has	  over	  450	  fewer	  
false	  positives	  (which	  lead	  to	  the	  discard	  of	  uninfected	  organs	  with	  concomitant	  loss	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of	  survival	  and	  QALYs	  and	  increased	  cost	  of	  care	  on	  dialysis)	  compared	  to	  NAT	  Only	  
and	  115	  fewer	  false	  positives	  that	  the	  Current	  Practice.	  This	  is	  at	  the	  expense	  of	  
having	  11	  more	  false	  negatives	  (transplanting	  infected	  organs)	  than	  NAT	  Only	  or	  3	  
more	  than	  the	  Current	  Practice.	  	  
	  
Overall,	  Selective	  NAT	  with	  ELISA	  will	  lead	  to	  the	  most	  transplanted	  organs	  and	  
fewest	  discarded	  organs.	  In	  terms	  of	  QALYs,	  Selective	  NAT	  with	  ELISA	  has	  the	  
highest	  number	  of	  associated	  QALYs	  (outside	  of	  the	  non-­‐viable	  screening	  option	  of	  
ELISA	  Only)	  and	  the	  least	  amount	  of	  QALYs	  discarded.	  When	  summing	  up	  the	  lost	  
QALYs	  due	  to	  false	  positives	  (difference	  between	  QALYs	  of	  dialysis	  and	  
transplantation)	  and	  accounting	  for	  the	  QALYs	  tied	  up	  in	  false	  negatives	  (all	  QALY	  
differences	  were	  gains	  associated	  with	  being	  transplanted	  with	  an	  infected	  organ	  
over	  dialysis),	  Selective	  NAT	  with	  ELISA	  lost	  the	  least	  amount	  of	  QALYs	  outside	  of	  
the	  ELISA	  Only	  strategy.	  In	  summary,	  Selective	  NAT	  with	  ELISA	  is	  the	  most	  cost-­‐
effective	  (outside	  of	  ELISA	  Only)	  screening	  strategy	  and	  is	  associated	  with	  more	  
transplanted	  organs,	  increased	  survival,	  most	  QALY	  gains,	  least	  QALY	  losses,	  and	  
least	  discarded	  organs	  at	  the	  cost	  of	  3	  more	  infected	  organs	  transplanted	  over	  the	  
Current	  Practice.	  
	  
There	  is	  a	  general	  public,	  as	  well	  as	  physician,	  fear	  of	  transmitting	  an	  infectious	  
disease	  to	  a	  transplant	  recipient.	  Not	  only	  is	  a	  physician’s	  creed	  to	  do	  no	  harm,	  but	  
there	  is	  concern	  about	  how	  a	  new	  infection	  will	  act	  in	  a	  newly	  and	  sustained	  
immunocompromised	  patient.	  	  For	  these	  reasons,	  UNOS	  has	  adopted	  the	  CDC	  HRD	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criteria	  to	  label	  organs	  for	  closer	  scrutiny	  that	  may	  be	  infected	  with	  HIV	  and/or	  HCV	  
and	  physicians	  have	  subsequently	  been	  more	  reluctant	  to	  use	  these	  organs.24,25	  
While	  it	  is	  known	  that	  HRD	  organs	  are	  at	  risk,	  it	  has	  been	  shown	  that	  that	  risk	  is	  still	  
relatively	  small16,24,27	  and	  so	  the	  lower	  use	  of	  HRD	  organs	  represents	  a	  discarded	  
pool	  of	  mostly	  uninfected	  organs	  that	  would	  serve	  to	  benefit	  those	  on	  the	  transplant	  
waiting	  list.	  A	  potential	  solution	  to	  the	  discarding	  of	  uninfected	  HRD	  organs	  has	  
been	  to	  use	  NAT	  which	  would	  more	  accurately	  identify	  uninfected	  organs	  and	  
thereby	  increase	  the	  willingness	  of	  transplant	  surgeons	  to	  use	  the	  donor	  organs.25	  
However,	  there	  has	  been	  a	  reluctance	  to	  accept	  universal	  NAT	  due	  to	  recent	  reports	  
pertaining	  to	  its	  high	  false	  positive	  rate,	  cost	  and	  laboratory	  turn-­‐around	  time.16,32,33	  	  
	  
False	  positive	  rates	  for	  NAT	  have	  been	  reported	  in	  the	  9-­‐57%	  range	  although	  these	  
quality	  control	  studies	  did	  not	  include	  HIV	  and	  were	  published	  from	  1993-­‐1997.31	  
Based	  on	  current	  NAT	  tests,	  we	  used	  a	  value	  of	  96.85%	  for	  NAT	  specificity	  which	  
corresponds	  to	  a	  false	  positive	  rate	  of	  3.15%.56	  	  
	  
As	  for	  the	  costs	  of	  NAT,	  a	  2009	  survey	  of	  OPOs	  revealed	  widely	  variable	  costs	  
depending	  on	  day	  or	  night	  testing,	  the	  volume	  of	  tests	  run	  and	  transportation	  costs.	  	  
The	  costs	  (including	  the	  test	  and	  transportation)	  ranged	  from	  $32	  to	  $9,662	  (in	  
2015	  US$)	  with	  a	  median	  cost	  of	  US$893.32	  According	  to	  our	  personal	  
communication	  with	  the	  Maryland	  OPO	  (personal	  correspondence,	  Karen	  Kennedy,	  
The	  Living	  Legacy	  Foundation	  of	  Maryland,	  March	  3,	  2013),	  the	  cost	  of	  NAT	  was	  $75	  
each	  for	  HIV	  and	  HCV	  with	  no	  other	  associated	  direct	  costs	  (these	  NATs	  were	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performed	  in	  the	  same	  laboratory	  and	  at	  the	  same	  time	  as	  other	  screening	  tests	  so	  
there	  was	  no	  additional	  transportation	  or	  handling	  costs).	  	  The	  Maryland	  OPO	  
reported	  cost	  of	  $75	  is	  about	  10%	  of	  the	  reported	  costs	  from	  the	  2009	  survey.	  	  
	  
The	  reportedly	  slow	  NAT	  turn-­‐around	  time	  has	  been	  due	  to	  two	  factors:	  the	  time	  
needed	  to	  perform	  the	  test	  and	  the	  need,	  in	  certain	  cases,	  to	  send	  the	  test	  to	  a	  
distant	  laboratory	  since	  local	  laboratories	  did	  not	  perform	  NAT.	  	  Of	  the	  OPOs	  that	  
responded	  to	  a	  2009	  survey,	  less	  than	  half	  reported	  always	  receiving	  NAT	  results	  
within	  12	  hours	  of	  blood	  draw.32	  In	  fact,	  according	  to	  a	  2008	  survey	  of	  58	  OPOs,	  
21%	  of	  OPOs	  stated	  that	  they	  would	  not	  be	  able	  to	  comply	  with	  mandatory	  NAT	  of	  
organ	  donors	  due	  to	  NAT	  result	  turnaround	  time.34	  As	  NAT	  becomes	  more	  common	  
and	  the	  technology	  becomes	  less	  expensive,	  it	  is	  likely	  that	  the	  same	  laboratories	  
that	  perform	  donor-­‐screening	  tests	  will	  include	  NAT	  as	  one	  of	  their	  panel	  and	  
thereby	  reduce	  the	  cost	  and	  turnaround	  time	  substantially.	  The	  question	  then	  
remains	  how	  best	  to	  use	  NAT	  as	  it	  becomes	  a	  much	  more	  accepted	  and	  utilized	  
screening	  test	  with	  the	  lasting	  cause	  for	  concern	  being	  its	  false	  positive	  rate.	  
	  
While	  the	  actual	  risk	  of	  WP	  infection	  in	  HRDs	  is	  low,	  the	  risk	  still	  exists	  as	  evidenced	  
by	  the	  2007	  transmission	  of	  HIV	  and	  HCV	  from	  one	  donor	  to	  four	  recipients	  due	  to	  
such	  a	  WP	  infection.21,22	  However,	  it	  should	  be	  noted	  again	  that	  living	  with	  HIV	  
and/or	  HCV	  is	  associated	  with	  more	  QALYs	  than	  remaining	  on	  dialysis	  and	  the	  
subsequent	  lifespan	  of	  those	  with	  the	  infections	  are	  longer	  than	  the	  lifespan	  of	  those	  
under	  treatment	  for	  ESRD.46,47	  So	  while	  it	  is	  never	  desirable	  to	  transmit	  infectious	  
	   	  
	   108	  
disease	  via	  solid	  organ	  transplantation,	  the	  fact	  remains	  that	  even	  in	  the	  face	  of	  
transmitted	  infection,	  the	  patient	  is	  usually	  still	  better	  off	  in	  terms	  of	  QALYs	  and/or	  
survival.	  	  This	  means	  that	  the	  pursuit	  of	  zero	  transmitted	  infections	  is	  likely	  not	  
desirable	  at	  the	  cost	  of	  too	  many	  lost	  uninfected	  organs,	  QALYS	  and	  survival	  so	  that	  
NAT	  should	  be	  used	  more	  sparingly	  than	  universally.	  	  
	  
However,	  when	  dealing	  with	  HRDs,	  the	  individual	  transplant	  candidate	  interests	  
would	  best	  be	  served	  by	  addressing	  two	  items:	  first,	  proper	  informed	  consent	  and	  
second,	  assuring	  the	  patient	  has	  a	  detailed	  understanding	  of	  whether	  they	  belong	  to	  
a	  patient	  subgroup	  that	  benefits	  from	  use	  of	  HRDs,	  even	  if	  receiving	  HIV	  and/or	  HCV	  
via	  transplantation.	  	  In	  terms	  of	  informed	  consent,	  UNOS	  mandates	  special	  informed	  
consent	  (SIC)	  from	  patients	  using	  HRDs.	  	  While	  one	  study	  discovered	  no	  decrease	  in	  
HRD	  utilization	  when	  using	  SIC57,	  informed	  consent	  might	  still	  be	  served	  by	  
presenting	  risk	  in	  everyday	  terms	  that	  patients	  might	  be	  better	  able	  to	  grasp.	  	  For	  
example,	  one	  academic	  study	  related	  the	  risk	  of	  death	  from	  contracting	  AIDS	  from	  
an	  HRD	  to	  common	  medications,	  occupations,	  modes	  of	  transportation	  and	  
recreational	  activities	  (e.g.	  the	  risk	  of	  death	  from	  AIDS	  from	  HRDs	  was	  less	  than	  the	  
risk	  of	  death	  from	  the	  use	  of	  Vioxx,	  having	  an	  occupation	  as	  a	  tree	  feller,	  riding	  a	  
motorcycle	  and	  just	  more	  than	  rock	  climbing).58	  Second,	  in	  terms	  of	  understanding	  
subgroups	  that	  benefit	  from	  accepting	  HRDs,	  a	  recent	  study	  explored	  via	  Markov	  
modeling	  and	  Monte	  Carlo	  simulation	  230,400	  patient	  phenotypes	  and	  generated	  an	  
online	  tool	  to	  assess	  subgroup	  risk	  and	  benefit	  of	  using	  HRDs	  based	  on	  ten	  recipient	  
characteristics	  and	  two	  donor	  characteristics.30	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There	  are	  several	  limitations	  in	  this	  analysis.	  	  First,	  the	  probabilities,	  utilities	  and	  
costs	  were	  drawn	  from	  different	  populations	  from	  the	  literature.	  	  As	  transmission	  of	  
disease	  via	  HRDs	  is	  so	  uncommon,	  we	  feel	  that	  literature-­‐based	  values	  from	  closely	  
related	  populations	  were	  appropriate.	  	  Secondly,	  there	  was	  no	  literature	  on	  the	  
QALYs	  of	  those	  kidney	  transplant	  patients	  infected	  by	  false	  negative	  HRD	  organs	  but	  
this	  was	  addressed	  by	  averaging	  a	  wide	  range	  of	  proxy	  QALYs	  in	  this	  analysis.	  	  
	  
Third,	  the	  willingness	  of	  transplant	  surgeons	  to	  use	  HRDs	  come	  from	  a	  survey	  
conducted	  in	  200825	  and	  while	  the	  difference	  in	  becoming	  a	  high-­‐utilizer	  of	  HRDs	  
due	  to	  the	  use	  of	  NAT	  was	  not	  found	  to	  be	  statistically	  significant	  in	  kidney	  
transplantation,	  this	  analysis	  assumed	  statistical	  significance.	  This	  approach	  
avoided	  the	  possibility	  of	  NAT	  resulting	  in	  decreased	  HRD	  use	  and	  the	  results	  of	  this	  
study	  showed	  that	  even	  if	  negative	  NAT	  did	  significantly	  increase	  HRD	  use,	  it	  was	  
still	  did	  not	  overcome	  the	  negative	  effect	  of	  the	  NAT	  false	  positive	  rate.	  	  Fourth,	  we	  
did	  not	  address	  discordant	  results	  between	  NAT	  and	  ELISA	  but	  since	  these	  instances	  
are	  very	  unlikely,	  it	  likely	  would	  have	  no	  effect	  on	  our	  results.	  Fifth,	  for	  the	  
simplicity	  of	  the	  model,	  the	  cost	  and	  loss	  of	  QALYs	  related	  to	  dialysis	  due	  to	  false	  
and	  true	  positives	  were	  overestimated	  as	  a	  true	  positive	  or	  false	  positive	  was	  
assigned	  a	  lifetime	  cost	  and	  QALY	  of	  dialysis	  although	  many	  of	  those	  patients	  would	  
get	  transplanted	  with	  an	  uninfected	  organ	  in	  subsequent	  years.	  This	  approach	  made	  
the	  difference	  between	  screening	  strategies	  more	  pronounced	  but	  should	  have	  no	  
effect	  on	  their	  relative	  cost-­‐effectiveness.	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Sixth,	  our	  model	  predicts	  a	  total	  of	  749	  infected	  organs	  (253	  from	  HRDs	  and	  496	  
from	  average	  risk	  donors	  resulting	  in	  8-­‐22	  transplants	  of	  infected	  organs)	  with	  an	  
additional	  0.3-­‐4	  for	  WP	  infections	  associated	  with	  NAT	  or	  ELISA	  assuming	  15,449	  
organs	  recovered.	  According	  to	  the	  OPTN/SRTR	  database	  for	  2013,	  a	  total	  of	  3,638	  
high-­‐risk	  donor	  organs	  were	  recovered	  with	  3,159	  of	  them	  being	  transplanted	  (an	  
86.8%	  utilization	  rate)	  which	  left	  479	  high-­‐risk	  organs	  discarded	  (unpublished	  data,	  
February	  28,	  2015).	  In	  this	  paper,	  we	  are	  arguing	  that	  there	  are	  uninfected	  HRDs	  
that	  are	  disposed	  of	  in	  the	  479	  that	  were	  discarded	  in	  2013,	  yet	  our	  expected	  
number	  of	  infected	  organs	  is	  higher	  than	  this.	  Clearly	  there	  would	  have	  to	  be	  in	  
excess	  of	  270	  infected	  organs	  transplanted	  for	  there	  to	  be	  only	  479	  HRDs	  discarded,	  
yet	  during	  the	  past	  twenty	  years,	  there	  have	  been	  at	  least	  7	  reported	  incidents	  of	  
viral	  disease	  transmission	  from	  a	  solid	  organ	  donor	  to	  transplant	  recipients21-­‐23	  
leaving	  a	  large	  gap	  between	  expected	  and	  observed	  infection	  transmission	  rate.	  	  	  
	  
The	  reason	  for	  the	  gap	  between	  expected	  and	  observed	  high-­‐risk	  organ	  infection	  
transmissions	  can	  be	  several-­‐fold.	  	  First,	  those	  deciding	  to	  donate	  organs	  may	  self-­‐
select	  in	  terms	  of	  those	  with	  HIV	  or	  HCV	  or	  those	  highly	  suspicious	  that	  they	  may	  
have	  HIV	  and/or	  HCV	  donate	  at	  much	  lower	  rates	  than	  those	  who	  are	  not	  infected	  or	  
are	  not	  suspicious	  that	  they	  have	  HIV	  and/or	  HCV.	  	  Another	  possibility	  is	  that	  the	  
risk	  of	  transmission	  of	  HIV	  and/or	  HCV	  from	  a	  donated	  organ	  is	  very	  low.59	  In	  order	  
to	  be	  conservative	  in	  this	  paper,	  we	  assumed	  100%	  transmission	  of	  infection	  from	  
infected	  organs	  to	  recipient	  as	  the	  tolerance	  of	  transmission	  of	  infection	  via	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transplantation	  is	  extremely	  low	  in	  practice	  and	  public	  opinion.	  A	  third	  option	  is	  
that	  transmitted	  infections	  are	  not	  discovered	  prior	  to	  patient	  death	  or	  are	  not	  
reported	  as	  the	  infection	  may	  have	  been	  assumed	  to	  be	  from	  other	  sources	  (e.g.	  
blood	  transfusions)	  rather	  than	  the	  transplant.	  A	  recent	  paper	  evaluating	  the	  use	  or	  
discard	  of	  HRD	  organs	  estimated	  2-­‐9	  WP	  infection	  transmissions	  per	  1000	  
recipients.	  28	  Also	  of	  note	  in	  that	  study	  was	  that	  transplanting	  all	  the	  HRDs	  lead	  to	  a	  
lower	  acquired	  infection	  rate	  than	  in	  the	  discard	  arm	  as	  the	  risk	  of	  acquiring	  HCV	  on	  
dialysis	  was	  greater	  than	  the	  risk	  of	  transplanting	  all	  of	  the	  HRD	  organs.28	  	  
	  
In	  conclusion,	  CDC	  HRD	  organs	  represent	  a	  category	  of	  organs	  whose	  increased	  use	  
could	  lead	  to	  additional	  uninfected	  kidneys	  being	  added	  to	  the	  donor	  pool	  each	  year.	  	  
The	  current,	  cumulative,	  individual	  HRD	  screening	  strategies	  employed	  by	  OPOs	  do	  
not	  provide	  a	  cost-­‐effective	  use	  of	  these	  organs.	  Across	  all	  OPOs,	  the	  collective	  
decisions	  between	  using	  universal	  NAT,	  selective	  NAT	  and	  ELISA	  only	  strategies	  do	  
not	  balance	  efficiently	  the	  tradeoffs	  between	  NAT	  cost,	  NAT	  availability,	  the	  effect	  of	  
NAT	  increasing	  transplant	  willingness	  to	  use	  HRDs	  and	  the	  effect	  of	  the	  false	  
positive	  rate	  associated	  with	  NAT.	  In	  addition,	  the Dartmouth Institute for Health 
Policy and Clinical Practice, the New England Healthcare Institute, McKinsey consulting 
and Thomson Reuters have all estimated that 30% of the national spending in health care 
could be eliminated by reducing unwarranted variation in healthcare practices (lowering 
spending to the level of low spending regions while maintaining equivalent quality).60 So 
by identifying the best strategy to screen for infections of HIV and HCV in donor kidneys, 
a national evidence-based policy could serve to cut wasted costs while improving or 
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maintaining the quality of health care delivered. Selective	  NAT	  with	  ELISA	  is	  the	  most	  
reasonable	  and	  cost-­‐effective	  screening	  strategy	  and	  the	  selective	  NAT	  use	  should	  
be	  determined	  at	  a	  national	  level.	  	  NAT	  use	  should	  be	  selective	  as	  the	  ratio	  of	  its	  
discovery	  of	  a	  false	  negative	  ELISA	  WP	  infections	  to	  its	  mislabeling	  of	  false	  positives	  
is	  very	  unattractive	  and	  detrimental	  to	  those	  on	  the	  waiting	  list.	  	  While	  transplant	  
physicians	  do	  not	  want	  to	  transmit	  infections	  via	  solid	  organ	  transplantation	  and	  
they	  want	  to	  keep	  such	  transmissions	  from	  being	  sensationalized	  in	  the	  media	  by	  
decreasing	  such	  transmissions,	  their	  obligation	  is	  also	  as	  stewards	  of	  the	  waiting	  list	  
and	  establishing	  guidelines	  to	  such	  an	  end	  is	  paramount.	  As	  we	  know	  that	  infectious	  
risk	  differs	  greatly	  (to	  over	  a	  thousand-­‐fold)	  even	  between	  high-­‐risk	  
behaviors,16,24,27	  we	  believe	  that	  a	  more	  nuanced	  selective	  use	  of	  NAT	  should	  be	  
established	  based	  on	  risk	  behavior	  and	  specific	  candidate	  population.	  	  This	  is	  
especially	  important	  as	  the	  transplant	  community	  moves	  toward	  including	  more	  
behaviors	  into	  the	  high-­‐risk	  category	  (such	  as	  recent	  sexually	  transmitted	  disease,	  
recent	  hemodialysis,	  tattooings	  from	  a	  non-­‐professional,	  and	  body	  piercings)61,62	  
which	  will	  lower	  transplant	  surgeon	  utilization	  of	  such	  organs	  and	  encourage	  more	  
NAT	  use	  which	  will	  lead	  to	  more	  discarding	  of	  uninfected	  organs	  due	  to	  the	  false	  
positive	  rate	  of	  NAT.	  We	  believe	  a	  national	  policy	  of	  selective	  NAT	  use	  will	  best	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APPENDIX 1. Detailed Calculations for Select Decision Tree Inputs 
 
NAT Availability 
For this value, we used the percentage of times that the NAT is “always” available for the 
transplant decision.  The two papers used did not just categorize “always” and “never” 
having the NAT results by the time of the transplant decision but they also included the 
percentage of times that the NAT results are available <10% of the time, 10-25% of the 
time, 25-50% of the time, 50-75% of the time and 75-99% of the time.  The goal of this 
study was to evaluate the effects of having NAT available, so we discarded the other 
categories since even if there was a 1% that the results of the NAT would not be back, 
that would violate the premise of this study in terms of using NAT for the transplant 
decision. 
 
NAT available for transplant decision  
1. HIV: The average of 0.3641 and 0.6322	  in always having the NAT results available at 
the time of the transplant decision was 0.498. The range was established by using the 
lowest reported value, 0.3641, and the highest reported value, 0.632.2  
2. HCV: The average of 0.3751	  and 0.5892	  in always having the NAT results available at 
the time of the transplant decision was 0.482. The range was established by using the 
lowest reported value, 0.3751, and the highest reported value, 0.589.2  
3. Combined: To be conservative, the lowest point value between HIV and HCV was 
used as the combined point value, 0.482.The range was established by using the lowest 
reported value, 0.3641, and the highest reported value, 0.632.2  
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Organ Use 
The probability of organ use based on the use of NAT with ELISA or just ELISA was 
taken from one paper published in 2009.3 A national survey was conducted between 
January and April of 2008 assessing the use of high-risk donor organs among transplant 
surgeons with hierarchical models examining the association between OPO NAT 
performance and high-risk donor use among that OPO’s transplant surgeons.  NAT 
performance was associated with a significantly higher odds of high-risk donor organ use 
when looking at pancreas, kidney, liver and simultaneous pancreas and kidney transplant 
(significance was lost when only looking at kidney use except in the use of commercial 
sex worker risk organs for HIV and HCV and for intravenous drug use risk kidneys for 
HIV).  Specifically, the increase in odds was measured for those who were “high 
utilizers,” or those who responded that they accepted more than 10% of “otherwise 
standard criteria offers from donors of this type” (high utilization was assessed by each of 
the seven high-risk behaviors) in the OPO’s that did not always use NAT as opposed to 
those OPO’s that always used NAT.  Of note, there was variation between HIV and HCV 
and the type of high-risk behavior as to whether those organs were used at greater 
frequency or not with NAT testing (e.g. organs exposed to HIV were rarely used and 
NAT testing did little to increase utilization of these organs). According to the article, 
NAT utilization increased the odds of surgeons being “high utilizers” of high-risk donor 
organs at risk for HIV by 1.52 (0.74-3.12) and for HCV by 1.30 (0.61-2.75).  We, 
however, turned these insignificant results to significant results by not accepting that 
NAT use would decrease kidney utilization and making the ranges instead for HIV 1.52 
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(1.01-4.30) and for HCV 1.30 (1.21-4.29). We felt comfortable doing this as we planned 
to explore the magnitude of change in high-risk organ utilization due to NAT in the 
sensitivity analyses in order to determine the value at which the increased utilization 
might affect the results of the study.  
 
The baseline utilization rate across the country of high-risk organs was determined by 
examining the OPTN/SRTR database for 2013. That year, a total of 3,638 high-risk donor 
organs were recovered with 3,159 of them being transplanted (an 86.8% utilization rate) 
which left 479 high-risk organs discarded (unpublished data, February 28, 2015). The 
range of utilization was then taken as 10% more or less than 86.8%. 
 
In order to determine the increase in probability of using high-risk organs with the use of 
NAT (or the decrease probability of using high-risk organs when using only ELISA), the 
current probability of using a high-risk organ according to the data from the SRTR for 
2013, 86.8%, was converted to odds by, “odds = [probability/(1-
probability)]=0.868/0.132=6.58”.  This value was then multiplied by the odds ratio point 
value and range for the increased use of HIV and HCV when using NAT.  These odds 
were then converted back to probabilities by using the equation, 
“probability=[odds/(1+odds)].” These differences were then added to the baseline 
probability of 86.8% to determine the increase in probability associated with using NAT 
or were subtracted from the baseline probability of 86.8% to determine the decrease in 
probability associated with using ELISA only. 
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Of note, since the increase and decrease in utilization probability based on using NAT or 
using only ELISA could only affect a certain group of OPO’s (e.g. the OPO’s that always 
use NAT could not increase their probability of using high-risk organs by using NAT 
because they already always use NAT), the increase and decrease in utilization 
probability was multiplied by the percentage of OPO’s that could be affected by a change 
in NAT usage policy. This meant that the increase in probability of high-risk organ usage 
when using NAT was multiplied by 0.25 (with a range of 0 to 0.33) to reflect the pool of 
utilizers that might be affected by NAT use (68.4% of OPO’s already always use NAT 
and 13.8-18.2% of OPO’s already use NAT selectively meaning only around 25% of 
OPO’s could be affected by changing their NAT policy from ELISA only). By corollary, 
the decrease from the baseline utilization of high-risk organs of 86.8% when using only 
ELISA was multiplied by 0.75 (with a range of 0.68-0.80) to establish the decreased 
probability of high-risk kidney use since using ELISA only would only affect those 
OPO’s who always used NAT (68.4%) or a portion who only selectively used NAT 
(13.8-18.2%). 
 
Tables 10-11 show the decrease in use of high-risk organs at risk for HIV and HCV, 
respectively, when using ELISA only from the baseline utilization rate of 86.8% as 
determined from the OPTN/SRTR 2013 data. Tables 12-13 show the increase in use of 
high-risk organs at risk for HIV and HCV, respectively, when using NAT from the 
baseline utilization rate of 86.8% as determined from the OPTN/SRTR 2013 data. 
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Table 10 - Decrease in Use of Kidneys at High-Risk for HIV When Using ELISA 
Only 
Probability of organ 
utilization 
68% NAT effect 75% NAT effect 80% NAT effect 
0.868 0.840 (0.801-0.867) 0.837 (0.794-0.867) 0.835 (0.790-0.867) 
Lower bound - 0.781 0.753 (0.714-0.780) 0.750 (0.708-0.774) 0.748 (0.703-0.780) 
Upper bound - 0.955 0.927 (0.888-0.954) 0.924 (0.882-0.954) 0.922 (0.877-0.954) 
 
 
Table 11 - Decrease in Use of Kidneys at High-Risk for HCV When Using ELISA 
Only 
Probability of organ 
utilization 
68% NAT effect 75% NAT effect 80% NAT effect 
0.868 0.850 (0.801-0.854) 0.848 (0.794-0.853) 0.846 (0.790-0.852) 
Lower bound - 0.781 0.763 (0.714-0.767) 0.761 (0.708-0.766) 0.759 (0.703-0.765) 
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Table 12 - Increase in Use of Kidneys at High-Risk for HIV When Always Using 
NAT 
Probability of organ 
utilization 
0% NAT effect 25% NAT effect 33% NAT effect 
0.868 0.868 (0.868-0.868) 0.878 (0.868-0.892) 0.882 (0.868-0.900) 
Lower bound - 0.781 0.781 (0.781-0.781) 0.791 (0.781-0.806) 0.794 (0.781-0.813) 
Upper bound - 0.955 0.955 (0.955-0.955) 0.965 (0.955-0.980) 0.968 (0.955-0.987) 
 
 
Table 13 - Increase in Use of Kidneys at High-Risk for HCV When Always Using 
NAT 
Probability of organ 
utilization 
0% NAT effect 25% NAT effect 33% NAT effect 
0.868 0.868 (0.868-0.868) 0.875 (0.873-0.892) 0.877 (0.875-0.900) 
Lower bound - 0.781 0.781 (0.781-0.781) 0.788 (0.786-0.806) 0.790 (0.788-0.813) 
Upper bound - 0.955 0.955 (0.955-0.955) 0.962 (0.960-0.980) 0.964 (0.962-0.987) 
 
 
For the combined HIV and HCV values, we referred to the data that 97% of the NAT pre-
window period infections were HCV and 3% were HIV.4 We used this data to weight the 
increased or decreased use of high-risk organs based on use of NAT or not as 97% of the 
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increased or decreased probability of using an HCV organ and 3% of the increased or 
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CHAPTER FOUR – MANUSCRIPT #3 
Identifying Appropriate Recipients for High Kidney Donor Profile Index Deceased 




Introduction: With the increasing disparity between transplant candidate numbers and 
kidneys available in the donor pool there has been interest in identifying transplant 
candidate subpopulations that would benefit from the utilization of high KDPI kidneys as 
a means to increase the donor kidney pool. 
 
Objectives: To establish the cost effectiveness of utilizing high KDPI kidneys in various 
transplant candidate subpopulations.  
 
Methods: A Markov model was developed, based on SRTR data from 2002-2011, that 
allowed 129,024 patient phenotypes to be evaluated as to their survival and QALY gain 
associated with accepting a deceased donor kidney with a KDPI of 51-60, 61-70, 71-80, 
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81-90 or 91-100. The same model also explored the cost effectiveness, in cost per 
QALYs, of transplanting these high KDPI organs into the specific patient phenotypes. 
 
Results: Cost-effectiveness, in cost per QALY gained, across all 129,024 phenotypes 
ranged from -$54 million to $43 million with a mean of -$154,600.  Seventy-seven 
percent of the scenarios evaluated resulted in cost savings per QALY gained. 56% of the 
phenotypes had positive additional survival and 87% of the phenotypes had cost savings. 
The main drivers of increased survival and QALYs stratified by KDPI were waiting time, 
PRA, and prior transplantation. 
 
Conclusions: Acceptance of even the highest KDPI kidney offers can confer survival 
benefit, QALY benefit and cost savings in some transplant candidate subgroups. It is 
important to identify and recognize these subgroups so that the kidney donor pool can be 
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Introduction 
The mismatch between donor kidneys available for transplantation and the number of 
transplant candidates on the waiting list continues to grow.  From 2011-2012, there was 
an increase of 7% in transplant candidates on the waiting list accompanied by a decrease 
in transplants leading to a disparity where demand was 2.7 times larger than the supply of 
kidneys.1 A number of initiatives have been pursued in order to increase and better utilize 
the scare resource of donor kidneys. One such initiative has been to classify kidneys 
outside of the standard criteria for transplantation in order to evaluate how those kidneys 
might be used to expand the donor pool by finding appropriate subpopulations of waiting 
list candidates for their use. From 2002 until 2012, the prevailing classification scheme 
for donor kidney quality and usage was the standard criteria donor (SCD) versus 
expanded criteria donor (ECD) 2 and since 2012, a more granular scale, the kidney donor 
profile index (KDPI), has been used2.  
 
In an effort to avoid discarding potentially useful ECD kidneys, multiple studies have 
explored the benefit of transplant candidates accepting ECD kidneys rather than 
remaining on the waiting list. One such study found that the adjusted long term relative 
mortality risk at 3 years was 60% lower for ECD kidney recipients than for those 
remaining on the waiting list (RR 0.4, 95% CI 0.37-0.44) and that ECD kidney offers 
were especially beneficial in specified subpopulations of waiting list candidates.3 This 
type of research and promoting of the use of ECD kidneys was successful as from the end 
of 2002 when the separate ECD waiting list was created to 18 months later, there was a 
15% increase in number of ECD transplants.4  
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A new, more granular deceased donor kidney quality scale, the KDPI, was introduced in 
2005 since the binary SCD/ECD classification system was found to misclassify donor 
kidneys in both directions.2 With a more granular classification system of donor kidneys, 
the same type of research was carried out to evaluate which subgroup of transplant 
candidates would benefit from high KDPI kidneys (graft survival decreases with 
increasing KDPI5) so as to avoid discarding potentially useful organs (donor kidneys with 
a KDPI score over 80 have a discard rate of approximately 50% in the U.S.6). A recent 
study found that recipients of KDPI organs of 71-80, 81-90, 91-100 reached break even 
points of cumulative survival at 7.7, 18, and 19.8 months after transplantation and had 
survival benefit thereafter.7 What is not known is the cost-effectiveness of transplanting 
high-KDPI kidneys while evaluating subpopulations defined by a greater number of 
patient parameters. 
 
The objective of this study was to evaluate the survival and quality adjusted life year 
(QALY) benefits that high KDPI kidneys offer to specific subpopulations on the waiting 
list as well as the costs associated with the transplantation of these kidneys. We believe 
that by showing a survival and QALY benefit at incrementally lower costs as compared 
to these patients remaining on the waiting list in certain subpopulations, we can 
encourage the appropriate use of high KDPI kidneys and thereby avoid them being 
discarded or further marginalized by increased cold ischemic time due to their offers 
being turned down before finally being accepted. By identifying and encouraging a more 
efficient use of the deceased donor kidney pool, we hypothesize that the donor pool can 
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effectively be increased with greater benefits to those on the waiting list and at decreased 
cost to society.  
 
Methods 
A Markov decision process model (Figure 8) was designed to estimate survival, quality 
adjusted life years (QALYs) and costs over a 60 month time horizon following a given 
patient’s and/or transplant surgeon’s decision to accept or decline a kidney within a KDPI 
range of 51-60, 61-70, 71-80, 81-90 or 91-100. During simulation, the patient could be in 
one of four Markov states: transplanted with a kidney of patient-desired KDPI range (T); 
waiting list (W); failed transplant returning to waiting list to remain there until becoming 
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Figure 8.  KDPI Offer Markov Decision Process Model  
 
* T = transplanted with desired KDPI range; W = waiting list; F = failed transplant; D  = 
death 
 
Waiting list and transplant population survival was based on observational data from the 
Organ Procurement and Transplantation Network/Scientific Registry of Transplant 
Recipients (OPTN/SRTR) database from January 1, 2002 through December 31, 2011.  
Patients registered after January 1, 1997 but before January 2002 were counted as late 
entries and contributed person-time starting in January 2002. Analysis was restricted to 
adults (≥ 18 years old), those receiving kidney-only transplants, and complete cases. 
Graft survival by KDPI strata was calculated for all kidneys made available since 2002 
with the median kidney used for calculations coming from the year 2011.  
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Follow up time and living status were based on the Social Security Death Master (SSDM) 
File and transplant center reports. Follow up time was counted as the longest follow up 
time as reported by the SSDM and transplant center. 
 
Survival was modeled for waiting list and failure state patients using Cox proportional 
hazards models while competing risk Cox regression models were used for survival for 
those with a transplant (Table 14). The survival transition probability from the waiting 
list was stratified by whether the transplant candidate had a previous transplant in order to 
account for non-proportionality. All probabilities were parameterized by patient age, sex, 
weight, height, BMI, blood type, race/ethnicity, panel reactive antibody (PRA), primary 
diagnosis leading to kidney failure, history of previous transplant and time on dialysis.  
All models had their survival analyses run for KDPI ranges of 0-50, 51-60, 0-60, 61-70, 
0-70, 71-80, 0-80, 81-90, 0-90, and 91-100. State transition models were validated, 
interactions were explored, and proportional hazards assumptions were verified using 
Martingale and Schoenfeld residuals. Time to transplantation from the waiting list with a 
kidney in the patient-desired KDPI range  (W2T) was based on user input and for the 
purpose of this model, waiting time was drawn from a gamma distribution with the 
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Table 14 - State Transition Probabilities 
Transition Description Source 
W2T Time to transplantation from waiting list with a 
patient-desired KDPI range donor kidney 
User input; for 
model, mode taken 
from a gamma 
distribution 
W2D Time to death from waiting list; stratified by 
whether there was a previous transplant; Cox 
proportional model 
SRTR data  
T2F Time to graft failure after transplant with a patient-
desired KDPI range donor kidney; competing risk 
model 
SRTR data  
T2D Time to death after transplant with a patient-
desired KDPI range donor kidney; competing risk 
model 
SRTR data  
F2D Time to death after graft failure in those patient 
who were either re-transplanted or remained on 
dialysis; Cox proportional model 
SRTR data  
 
 
QALYs were taken from a recent systematic review, meta-analysis and meta-regression 
of 190 studies evaluating patients undergoing various treatments for chronic kidney 
disease.8 Transplantation had a mean utility of 0.82 (95% CI 0.74-0.90) and hemodialysis 
had a mean utility of 0.70 (95% CI 0.62-0.78).  The W state used the same mean utility 
value as the hemodialysis and the D state had no QALYs associated with it.   
 
Cost prediction models were built independently from the state transition probability 
models using the United States Renal Data System (USRDS) Medicare Payment Data for 
Parts A, B and D data from January 1, 2006 through December 31, 2010. All patients had 
at least one year of follow-up through December 31, 2011. Cost data was only collected 
for those who were using Medicare as their primary insurance during our enrollment 
period. 
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The cost prediction models predicted the cost per patient per month based on the state (T, 
W and F), specific T state costs where applicable (the T status was broken into three 
parts; first, the one time cost of the transplant associated admission, the monthly cost 
during the first year post transplant and the monthly cost for year 2-3 post transplant with 
this last number being used for years 4 and 5 as well), the individual patient 
characteristics (age, sex, race/ethnicity, primary diagnosis leading to renal failure, PRA, 
height, weight, BMI), and the KDPI strata (0-50, 51-60, 61-70, 71-80, 81-90, 91-100). 
Two additional models accounted for the cost of transplant admission and the cost after 
graft failure. Each model with its total number of observations and R-squared values are 
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Table 15 - Cost Prediction Models with Total Number of Observations and R-
Squared Values 
Cost model Observations R-squared values 






T state (first year from transplantation) 29,565* 0.0310-0.0472 
T state (years 2-3 from transplantation) 21,726 0.0299-0.0633 
W state 67,267 0.0245 
F state 3,016 0.0493-0.1491 
Part D, T state (first year from 
transplantation) 
21,773 0.0203-0.0600 
Part D, T state (years 2-3 from 
transplantation) 
16,956 0.0687-0.0939 
Part D, W state 52,638 0.0217 
Part D, F state 2,266 0.0359-0.1922 
 
*Number of observations for T state (first year from transplantation) is larger than T state 
(primary admission costs for transplantation operation) as some individuals became 
eligible for Medicare after their transplantation. 
 
 
In validating our costs, we compared them to published Medicare data.9 The cost of 
dialysis via our model was $82,544 for one year compared to the USRDS Annual Data 
Report (ADR) 2013 Medicare value of about $75,000, our first year transplantation cost 
was $115,675 compared to the Medicare ADR value of $116,971 and our cost of 
transplantation per year for years 2 and 3 was $23,208 per year compared to the Medicare 
ADR value of about $20,000 all in 2011 U.S. dollars. All costs were reported in U.S. 
dollars discounted at 3% using 2011 as the base year.  
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Monte Carlo Simulation 
Kaplan-Meier curves were generated from simulating each patient phenotype 1,000 times 
over a 60-month time horizon in 1-month intervals. The simulation was run for all the 
possible combinations of phenotypes (129,024) as well as each phenotype at five KDPI 
strata (51-60, 61-70, 71-80, 81-90 and 91-100) leading to 645,120 scenarios. Generated 
results included life-years gained, QALYs gained, and cost per QALY gained following a 
patient’s decision to accept or reject a certain KDPI threshold.  
 
Incremental survival, QALYs, costs and cost per QALYs 
Ranges of minimum to maximum incremental survival, QALYs and costs at 5 years were 
calculated using a one percent sample of those who entered the waiting list between 
January 1, 2006 and December 31, 2010 (n=853). The percentage of those on the waiting 
list expected to benefit from increased survival, increased QALYs, decreased costs and 
negative cost per QALYs were then calculated from the same population. 
 
Classification and Regression Tree Analysis (CART) 
In order to determine the most important drivers of patient survival and QALYs, CART 
analysis was performed. The Markov model results of all 129,024 phenotypes were 
analyzed by CART as well as the Markov model results when stratified by KDPI range. 
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Statistical Analysis 
State transition probability analyses for survival were performed using STATA 12.0 
(StataCorp LP, College Station, Texas). Cost modeling was performed using STATA MP 
13.1 for Linux (StataCorp LP, College Station, Texas). The Markov model and Monte 
Carlo simulations were performed using C-plus-plus (Bjarne Stroustrup, Bell Labs). 
CART analysis was performed using R 2.14 (The R Foundation for Statistical Computing, 




The Markov decision process model was implemented allowing for 129,024 transplant 
candidate phenotypes based on the user input of age, sex, body mass index (BMI), blood 
type, race/ethnicity, panel reactive antibody (PRA), whether they had a previous 
transplant, primary diagnosis leading to renal failure and estimated months on the 
transplant waiting list. These phenotypes were then paired with one of five different 
KDPI strata (51-60, 61-70, 71-80, 81-90 and 91-100; based on donor age, height, weight, 
race/ethnicity, history of hypertension, history of diabetes, cause of death, serum 
creatinine, hepatitis C status and donation after circulatory death status) resulting in a 
total phenotype compliment of 645,120 scenarios. Once inputted into the model, survival 
curves were generated for a transplant candidate either accepting or rejecting an organ 
offer of specific KDPI range. The model also was able to determine quality-adjusted life 
years (QALYs) and cost-effectiveness over the same five year time period as the survival. 
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The following figures demonstrate survival curves for two different phenotypes (Figures 
9-10). 
 
Figure 9 - Expected Survival, Example 1. Expected survival after a deceased donor 
kidney offer at 5 years for a 40-year old female, BMI 25, blood type O, African 
American, PRA of 0, renal failure from diabetes, no prior transplant and with an 
estimated time on the waiting list of 24 months for either accepting or rejecting an organ 
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Figure 10 - Expected Survival, Example 2. Expected survival after a deceased donor 
kidney offer at 5 years for a 70-year old female, BMI 35, blood type A, Caucasian, PRA 
of 30, renal failure from glomerulonephritis, with a prior transplant and with an estimated 
time on the waiting list of 36 months for either accepting or rejecting an organ with a 




In Example 1, there is a survival advantage by accepting an organ with a KDPI of less 
than 60 (graphs for KDPI 61-70, 71-80 and 81-90 not shown) while anything higher than 
a KDPI of 61 offers no distinct survival advantage and likely even worsens survival. In 
Example 2, there is a clear survival advantage in accepting any organ with any KDPI. 
From Table 16, it is also seen that there is a cost savings associated with accepting any 
organ with any KDPI through all four examples. 
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Table 16 - Increased Number of Lives and Cost Savings Associated with Accepting 
Any KDPI Threshold According to the Phenotypes Detailed in Figures 9-10 
 Increase in those alive by 
accepting 
Cost savings per person  
by accepting 
Example 1   
KDPI 51-60 54 $134,35 
KDPI 91-100 -16 $79,914 
Example 2   
KDPI 51-60 376 $217,333 
KDPI 91-100 347 $189,736 
 
 
Survival, QALYs, Cost and Cost per QALY 
Incremental survival, QALYs and costs were measured as additional percentage points of 
survival, additional QALYs, and additional cost, respectively, at 5-years for those 
accepting as opposed to rejecting a donated kidney of specified KDPI range for the 
645,120 phenotypes stratified by KDPI range. Table 17 shows the incremental 5-year 
survival, QALY and cost associated with each KDPI strata and the percentage of 
phenotypes that would benefit from receiving a donated kidney from the specified KDPI 
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Table 17 - Incremental Survival, QALY, Cost and Cost per QALY by KDPI Range 
at 5 Years for All Generated Phenotypes. Results are displayed as “range; mean 
(percentage of those on the waiting list receiving the benefit of increased survival, 
increased QALYs, decreased costs, negative cost per QALY or negative cost per 
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Graphs for the incremental cost per incremental survival and incremental cost per 
incremental QALY at 5 years for those accepting as opposed to rejecting a KDPI of a 
certain range are shown below (Figures 11-12).  Of note, the same graphs stratified by 
only KDPI 91-100 are shown adjacent to the overall graph to show how the worst quality 
organs perform. 
 
Figure 11 - Cost-Effectiveness in Incremental Cost to Incremental Survival Gain at 
5 Years. The overall combination of all KDPI stratae are shown in A) and the KDPI 
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Figure 12 - Cost-Effectiveness in Incremental Cost to Incremental QALY Gain at 5 
Years. The overall combination of all KDPI stratae are shown in A) and the KDPI strata 





Survival, QALYs, Cost and Cost per QALY Applied to Waiting List 
Incremental survival, QALYs and costs were measured as additional percentage points of 
survival, additional QALYs, and additional cost, respectively, at 5-years for those 
accepting as opposed to rejecting a donated kidney of specified KDPI range for a one-
percent sample population of those who entered the waiting list from January 1, 2006 to 
December 31, 2010. Table 18 shows the incremental 5-year survival, QALY and cost 
associated with each KDPI strata and the percentage of waiting list candidates who would 
benefit from receiving a donated kidney from the specified KDPI strata. Cost per QALY 
was also calculated. 
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Table 18 - Incremental Survival, QALY, Cost and Cost per QALY by KDPI Range 
at 5 Years for All Those on the Waiting List. Results are displayed as “range; mean 
(percentage of those on the waiting list receiving the benefit of increased survival, 
increased QALYs, decreased costs or negative cost per QALY).” 
 
 Incremental survival  Incremental 
QALY 




-6.8 % - 40.2%; 
11.1% (96.2%) 











-17.8% - 34.4%; 
8.9% (90.7%) 











-26.3% - 33.2%; 
8.4% (90.9%) 











-27.6% - 32.8%; 
5.8% (80.4%) 








-43.2% - 31.9%; 
4.7% (68.9%) 








CART: Most Important Factors in Survival 
While all the transplant candidate factors affect 5-year survival, CART analysis identified 
the factors of most importance as estimated waiting time of 30 months, PRA of 90, age of 
55 and prior transplant status.  There was a 6.6% 5-year survival advantage for a 
transplant candidate to decline any organ with a KDPI of 50 or higher if they had an 
estimated time waiting time less than 30 months and a PRA over 90.  There was a 24% 5-
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year survival advantage in accepting any organ with a KDPI over 50 if their estimated 
waiting time was over 30 months, they had a PRA under 90, they were over 55 years old 
and were previously transplanted.  Of note, KDPI was not identified as one of the most 
influential factors in 5-year survival by CART analysis. 
 
CART: Most Important Factors in Survival Stratified by KDPI Range 
The most important factors influencing 5-year survival stratified by KDPI included 
estimated waiting time of 15 or 30 months, PRA of 45 and 90, prior transplantation, 
race/ethnicity, age of 35, 45, 55, 65 and 75, blood type, and diagnosis leading to renal 
failure. The CART diagram for the KDPI stratification of 51-60 is shown in Figure 13.  
The CART diagram for the Survival Benefit of Accepting KDPI 50 shows an additional 
5.1% survival at 5 years for accepting a kidney with KDPI of 51-60 after evaluating a 
total of over 129,000 phenotypes.  Declining a kidney with a KDPI of 51-60 is a better 
option as there is a 2% added survival advantage at 5 years for those who have an 
estimated waiting time to transplantation of less than 30 months and who has a PRA over 
90 (17% of the 129,000 phenotypes see this advantage).  Accepting a kidney with a KDPI 
of 51-60 is a better option as there is a 20% added survival advantage at 5 years for those 
with an estimated waiting time to transplantation of over 30 months, a PRA less than 90 
and are Caucasian (8% of the 129,000 phenotypes see this advantage) or for those with an 
estimated waiting time to transplantation of over 30 months, a PRA less than 90, are 
African American or Hispanic, with a prior transplantation and are over the age of 45 
(5% of the 129,000 phenotypes see this advantage). 
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Figure 13. CART Analysis Demonstrating the Most Influential Drivers of Survival 
Stratified by KDPI Range 
 (*ettx = estimated months on waiting list, ethn blc = African American, ethn hsp = 
Hispanic,  ethn wht  = Caucasion, prev_tx=0 mean no prior transplant while prev_tx=1 
mean prior transplant, abo = blood type specified as A, B, O and AB, dx = diagnosis as 
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CART: Most Important Factors in QALYs Stratified by KDPI Range 
The most important factors influencing 5-year QALYs stratified by KDPI included 
estimated waiting time of 15, 21 and 30 months, PRA of 45 and 90, prior transplantation, 
race/ethnicity, age of 45, 55, and 65, blood type, and diagnosis leading to renal failure. 
The CART diagram for the KDPI stratification of 51-60 is shown in Figure 14. The 
CART diagram for the QALY Gained by Accepting KDPI 50 shows an added 0.34 
QALYs at 5 years for accepting a kidney with KDPI of 51-60 after evaluating a total of 
over 129,000 phenotypes.  There is no scenario associated with fewer QALYs so it is 
always advantageous to accept an organ of KDPI 51-60 in terms of QALY gains at 5 
years.  The most number of additional QALYs are experienced by those who accept a 
kidney with a KDPI of 51-60, have a waiting time to transplantation over 30 months, 
have a PRA less than 90 and are Caucasian as they experience an additional 0.83 QALYs 
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Figure 14 - CART Analysis Demonstrating the Most Influential Drivers of QALYs 
Stratified by KDPI Range 
 
(*ettx = estimated months on waiting list, ethn blc = African American, ethn hsp = 
Hispanic,  ethn wht  = Caucasion, prev_tx=0 mean no prior transplant while prev_tx=1 
mean prior transplant, abo = blood type specified as A, B, O and AB, dx = diagnosis as 
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Discussion 
Utilization of high KDPI kidneys (defined as any KDPI over 50) can offer survival and 
QALY advantage to a substantial group of transplant candidates at the same as providing 
a cost savings advantage to Medicare. Over 77% of the 129,024 phenotypes studied 
enjoyed cost savings to QALYs gained, 56% experienced a survival advantage and 87% 
realized an overall cost savings. Overall survival advantage was not driven by KDPI, but 
rather the most important factors in order of importance were waiting list time, PRA, age 
and prior transplantation. When stratified by KDPI range, the main drivers of survival 
and QALY were waiting list time, PRA, prior transplantation and race/ethnicity. 
 
The growing disparity between the number of transplant candidates and available donor 
organs has lead to continued interest in how to increase and better utilize the scarce 
resource of donated kidneys. While some initiatives have sought to increase the donor 
supply (e.g. public awareness campaigns designed to encourage people to sign their 
drivers license as organ donors, encouraging living donation, evaluating theoretical 
markets for organs), others have sought to better utilize the organs that are already 
donated (e.g. establishing benefits of ECD or high KDPI kidneys, “longevity matching,” 
and use of high infectious-risk organs). This paper focused on the more efficient 
utilization of donated kidneys by evaluating the utility and cost-effectiveness of using 
high KDPI kidneys as compared to the same individual remaining on the transplant 
waiting list even in the face of high KDPI kidneys conferring lower graft function as 
compared to lower KDPI kidneys.10 Because while a lower quality organ confers lower 
	   	  
	   155	  
graft function and graft survival, their use can still provide overall survival, QALY and 
cost advantages to the transplant candidate compared to remaining on the waiting list. 
 
Lower quality organs (as measured by ECD or KDPI) lead to lower graft function and 
survival due to higher rates of delayed graft function, more acute rejection episodes, 
decreased long term graft function, prolonged cold ischemia time, increased 
immunogenicity, impaired ability to repair tissue and impaired function.11 So naturally, 
transplant surgeons and transplant candidates are more likely to turn down non-ideal 
organs.  It is known that ECD and high KDPI kidneys are refused at a higher rate than 
SCD and lower KDPI kidneys.6,11 Studies have shown that ECD organs confer survival 
benefit to at least some subgroups of transplant candidates over them remaining on the 
waiting list leading to a lower relative mortality resulting in 3-10 extra life years.3,12 
Similarly, a recent paper found that using high KDPI organs (71-80, 81-90, 91-100) in 
transplant candidates compared to remaining on the waiting list was associated with 
higher cumulative survival at 5 years in all three high KDPI groups.7 Of note, while 
ECDS account for 15% of deceased donor organs, almost a third of ECDs have a KDPI 
of less than or equal to 85 and almost 5% of SCDs have a KDPI over 85.2,5 
 
It now appears that the KDPI is gaining traction as the new standard for risk stratification 
of deceased donor kidneys.  In March 2012, the Organ Procurement and Transplantation 
Network (OPTN) began including KDPI in DonorNet® at the time of organ offers to 
assist in assessing quality of deceased donor kidneys as well as to assist in “longevity 
matching.”2 Another utility of having a reliable and granular scoring system is that a 
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patient and provider should be able to prospectively discuss the risks and benefits of 
kidneys of different KDPI scores so that the candidate can determine the maximum 
degree of risk they are willing to accept according to KDPI score in terms of survival and 
QALYs. 
 
There are several limitations to our paper.  First, we used a model to simulate outcomes 
instead of reporting observed outcomes from a randomized control trail.  We chose the 
modeling approach because it would not be possible to perform a prospective study 
where all 129,024 phenotypes of transplant candidates were assigned to accept or refuse a 
certain KDPI range and then to compare them to their counterfactual in any amount of 
reasonable time (not to mention cost nor ethical issues). While modeling may not reflect 
reality exactly, we feel that this model is a reasonable reflection as it was driven by data 
from a very large and comprehensive database, the Organ Procurement and 
Transplantation Network/Scientific Registry of Transplant Recipients (OPTN/SRTR) 
database. The model was tested for face validity and found to report survival, QALYs 
and costs reflecting the increase in survival and QALY and decrease in cost known when 
comparing transplantation to dialysis. Transition probability models were also tested for 
interactions and varying functional forms and competing risk models were used where 
appropriate. 
 
Second, our costs were taken from the Medicare Payment Data of the United States Renal 
Data System and we only included those who had Medicare as their primary insurance 
provider. When calculating Medicare Part D costs, the population used was a subset of 
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those with Medicare as their primary insurance.  While we only capture costs associated 
with Medicare recipients who use Medicare as their primary insurance, this represents a 
majority of those with end-stage renal disease.  We felt that this was appropriate as we 
reported results in terms of cost to Medicare rather than cost to society. 
 
Third, the R-values of our cost model were low meaning that they did not account for 
most of the variability in costs. However, the models did account for a number of patient 
and donated organ characteristics which made for a much better estimate of cost rather 
than just using the average cost across all patients. 
 
Fourth, transplant recipients are only eligible for Medicare until their third anniversary 
from their transplant date.  Our model used a 5-year time horizon so we used the 
Medicare year 2 and 3 costs per patient for years 4 and 5 as well.  This seems to be 
appropriate as the first transplant year costs are significantly higher than the other years, 
but then the costs over the next two years are relatively stable so that Medicare reports 
those costs as the same for years 2 and 3. Since costs immediately stabilize in years 2 and 
3, we felt that using the same stable costs for years 4 and 5 was acceptable. 
 
Fifth, while use of high KDPI kidneys confer 5-year survival and QALY advantage, it is 
recognized that this is at the expense of increased short-term mortality.7 So the results of 
this model should be interpreted with care by individual patients and physicians in light 
of this fact. 
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The findings of this study demonstrate that there is a wide range of high KDPI organs 
that can provide increased survival and QALYs even with decreased costs for a large 
group of subpopulations on the waiting list. The increased use of appropriate high KDPI 
kidneys in transplant candidates can represent a more efficient use of the donated organ 
pool and result in better candidate utility and cost savings to Medicare. 
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CHAPTER FIVE – DISCUSSION ON METHODS 
 
Literature Review Methods 
Literature review many times is the first step in identifying or evaluating a topic of 
interest. When performing or communicating the results of such a search, it is helpful to 
follow a guideline-driven evaluation process. A well-used process to evaluate a specific 
topic by collating the evidence over a broad range of literature is the systematic review.  
However, another reason to review the literature might be to evaluate the breadth of 
research on a topic, determine if a full systematic review should be pursued, summarize 
research findings or identify gaps in the literature,1 and in this case, a scoping review 
would be favored.  
 
Scoping reviews were first formally advanced in 2005 by Arksey and O’Malley.1 In their 
2005 paper, they established guidelines for this type of review to make a uniform 
approach of the many different types of literature reviews that were being conducted 
under the headings of systematic review, meta-analysis, rapid review, literature review, 
narrative review, research synthesis and structured review. They put forth five stages to 
be included in a scoping review that included identifying the research question, 
identifying relevant studies, study selection, charting the data, and collating/summarizing 
then reporting the results. In terms of collating data, they used nine headings 
(interventions, sample sizes, participants, research methods, outcomes, evidence relating 
to effectiveness, economic aspects, UK studies and gaps in the research). Identification of 
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research gaps was centered around the literature review by comparing topics across 
interventions and study designs as well as the optional stage of expert consensus. 
 
A subsequent paper in 2010 by Levac et al. sought to advance the methodology of 
scoping reviews in order to create consistency and to encourage others to participate in 
this type of review.2 Their contributions, by “stage” as laid out by Arksey and O’Malley, 
were to clarify and link the research question with the purpose, recognizing balance of 
comprehensiveness with feasibility, using the iterative approach in study selection and 
data extraction, having a numeric summary and qualitative analysis of the results, 
considering the policy applications, and using stakeholder consultation in order to 
translate the research results. 
 
As scoping reviews are still undergoing methodologic evolution, we turned to systematic 
review standards in order to carry out our scoping review. The PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) checklist and flow diagram 
were used for their intended consequences of creating transparency, standardization of 
steps and making reporting of results understandable and uniform across the literature. 
The checklist and worksheet can be found at www.prisma-statement.org.   
 
The AHRQ guidelines for gaps analysis were made for systematic reviews,3 but they 
were modified in our article to accommodate scoping reviews. The framework included 
identifying study characteristics such as population, intervention, comparison group, 
outcomes, and setting.  Then a gap reason was assigned to that study from one of four 
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choices: insufficient or imprecise information, biased information, inconsistency or 
unknown consistency, and not the right information. Since systematic reviews focus on 
one question in a certain sub-population, the gaps analysis guidelines had to be widened 
in order to accommodate the breadth of scoping reviews (e.g. populations became adult 
versus pediatric for the scoping review instead of “gestational diabetes in women over the 
age of 40,” for example, in a systematic review).  
 
Economic Evaluation Methods 
Economic evaluation is meant to help guide decision makers by relating the relationship 
between an intervention’s cost and effect. While comparative-effectiveness research 
compares effectiveness outcomes, cost-effectiveness determines the cost associated with 
the effectiveness of the outcomes as well. There are several methods used in cost-
effectiveness and include, to name a few, decision tree modeling, Markov modeling, 
difference-in-difference evaluation and instrumental variables approach. This thesis used 
a decision tree model as well as a Markov model in two separate cost-effectiveness 
analyses. 
 
Cost-effectiveness can also serve to establish uniform practices in a health field marked 
by variation in treatments. The Dartmouth Institute for Health Policy and Clinical 
Practice, the New England Healthcare Institute, McKinsey consulting and Thomson 
Reuters have all estimated that 30% of the national spending in health care could be 
eliminated by reducing unwarranted variation in healthcare practices (lowering spending 
to the level of low spending regions while maintaining equivalent quality).4 The 
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importance of this type of analysis is underscored by the existence of such groups and 
agencies that support this type of research like the Agency for Healthcare Research and 
Quality (AHRQ) on the U.S. federal level, the Institute for Clinical and Economic 
Review, and the New England Comparative Effectiveness Public Advisory Council as 
well as the fact that the 2009 U.S. government stimulus package included $1.1 billion for 
comparative effectiveness research.5 
 
When choosing an economic analysis approach, there are a number of methods to choose 
from: cost analysis, cost-effectiveness, cost-utility and cost-benefit. Cost analysis 
evaluates cost with no measurement of outcomes.  Cost-effectiveness evaluates both costs 
and outcomes with outcomes being measured per unit of specified result (e.g. outcome 
units of QALY, blood pressure points, years of survival).  Cost-utility is a type of cost-
effectiveness that evaluates both costs and outcomes with outcomes being measured as 
utilities (relative values of health states; most commonly used utility used is the quality 
adjusted life year or QALY). Cost-benefit analysis evaluates cost and outcomes with the 
outcomes converted to a monetary value. 
 
Costs can include direct, indirect, and/or intangible costs. It is important to specify all 
costs that will be included and to assure that all costs that are incrementally different 
between the two interventions are included. Costs should all be discounted and reported 
in a uniform currency in a specific year. It is also important to specify the perspective of 
the analysis, meaning who is gaining the effect and who is paying for it. Common 
perspectives include that of the individual, the payer (in this thesis, that would be 
	   	  
	   165	  
Medicare) or society. The societal perspective includes not just costs of interventions and 
outcomes, but also the effect and costs of how that intervention fits in a societal context 
to include patient ability to be in the workforce, cost of informal caretakers for the 
patients, work absenteeism, and unintended consequences of the intervention, to name 
just a few. 
 
Utility has been measured in the literature by QALY (one QALY equals living one year 
in perfect health), disability-adjusted life year (DALY; it is the years of life lived with a 
disability and the years of life lost with one DALY equivalent to one year of healthy life 
lost), healthy years equivalent (HYE; the amount of life in perfect health followed by 
immediate death that is equivalent to a lifetime in a diseased health state) and saved-
young-life equivalent (the number of individuals deemed necessary with improved health 
to equal the saving of one young person’s life).6 There remains some controversy 
regarding the discounting of QALYs.7 
 
QALY utility weights are evoked through time-trade-off, standard gamble and visual 
analogue scale.  In all scenarios, individuals are asked their preference of living in certain 
health states or death as opposed to those health states.  For time-trade-off, individuals 
are asked if they would prefer to remain in diseased health for a period of time, or to be 
restored to perfect health accompanied by a loss of years of life.  Standard gamble asks 
the individuals if they would accept a treatment that could return them to perfect health or 
kill them as opposed to remaining in a diseased health state.  The visual analogue scale 
merely asks individuals to rate a health state on a scale of 0 (death) to 100 (perfect health). 
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When performing a cost-effectiveness analysis, there is always the determination of 
whether the resultant cost-effective ratio is acceptable based on society’s willingness to 
pay. Willingness to pay does not mean that interventions are sought that do not cost 
anything, but that interventions are paid for according to the value placed on them.  Since 
many cost-effectiveness analyses are in cost per unit QALY, there should be a single 
value or range of costs that are willing to be paid for for any QALY. In the United 
Kingdom, the National Institute for Health and Clinical Excellence uses a general 
guideline of £20,000-30,000 (US$31,000-46,000) per QALY8 as their threshold of cost-
effectiveness.  While there is an historical $50,000 per QALY cost-effective threshold 
used in the US literature,9 the 2010 Patient Protection and Affordable Care Act 
specifically directs the newly formed Patient-Centered Outcomes Research Institute that 
no dollars per QALY threshold is to be used to determine recommendations for cost-
effectiveness.10 Another way to look at cost-effectiveness is to compare cost per QALY 
across other, common medical treatments or screenings.  For example, colonoscopy 
screening every ten years for colorectal cancer (as compared to no screening) has a cost-
effectiveness of $10,633-26,693 per QALY,11 targeted digital mammography screening 
for breast cancer (as compared to all-film or all-digital screening strategies) has a cost-
effectiveness of $21,000-33,000 per QALY,12 and coronary artery bypass grafting has a 
life-time cost-effectiveness of $6,791 per QALY.13 
 
As with most research methods, there are guidelines in how to conduct and report the 
outcomes of cost-effectiveness research in order to aid in the standardization of study 
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methods and to facilitate the ease of understanding reported results in the literature. One 
example is the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) that has developed such guidelines.14  
 
When evaluating multiple variables, decision tree analysis and Markov modeling are two 
common methods to employ. Decision trees are helpful in structuring a course of events 
with multiple decision or outcomes branch points. Each branch is assigned a probability 
and the cohort then proceeds from the decision node down the branches to establish how 
many end up in each resultant state with the associated effectiveness and cost. However, 
decision tree models do not handle well explicit time lapse, continuing risk, competing 
risk over time, and alternate events over time.15 In those cases, Markov modeling is 
helpful. 
 
A Markov model consists of mutually exclusive health/disease states where individuals 
transition between states based on transition probabilities where the final state almost 
always is death. The individuals accumulate the attributes of the states they are in (e.g. 
cost, QALY, survival) based on the amount of time they spend in each state. In this 
manner, it is possible to predict outcomes for a cohort of patients over a defined period of 
time. One potential downside of Markov modeling is the “Markov assumption” where the 
model does not account for when or from what state the individual transitions once they 
transition to another state.  This means that for any differential risk based on timing or 
prior state need to be built in by adding more states to the Markov model or that a form of 
dependency needs to be built into the transition probabilities.15 
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Transition probabilities determine how the cohort moves from one health state to another 
in Markov models and are survival models based on proportional or competing risks of 
the outcome of, basically, treatment failure or death. Model building is carried out in the 
standard fashion of data cleaning, population selection, parameter selection, regression 
evaluation for term interaction, confirmation of proportionality when using Cox 
proportional hazards and model validation.  
 
Competing risk models are an alternative to Cox regression in survival analysis.16 
Competing risk regression accounts for outcomes other than the one of interest (e.g. 
recurrence after infectious disease treatment) in a fashion that is distinct from the 
censoring that occurs in Cox regression.16 The key is that the risk group in the competing 
risk model is reduced with the occurrence of the competing risk or event whereas in the 
Cox regression the censored data is still considered to be at risk for the event of interest. 
When using Cox regression, the assumption of the censored individuals not contributing 
to the “at risk” group can be safely assumed if the only outcome of interest is death. Of 
note, in Cox regression, there is the also the assumption of proportionality where the 
hazard of the event of interest varies multiplicatively with a change in covariate (meaning 
the hazard ratio is constant over time).  Since proportionality does not always hold, it 
needs to be explored and verified prior to finalization of the survival model.  
 
Proportionality can be explored using graphical data where Kaplan-Meier observed 
survival curves are visually compared to Cox predicted survival curves for the same 
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covariate and if the curves are visually close to each other, then the assumption of 
proportionality is likely not violated. “Log –log” plots can also be used to assess the 
proportionality assumption where the log-log of survival versus the log of analysis time 
are plotted together and if the lines are reasonable parallel, then the assumption of 
proportionality is likely not violated.  
 
Another test of proportionality is the Schoenfeld residuals test where independence is 
tested between scaled residuals and time where an outcome of a slope of zero confirms 
the proportionality assumption. Schoenfeld residuals are the difference between observed 
and expected values of failure for each individual for each covariate.  As long as there is 
a random pattern in these residuals over time, then the assumption of proportionality has 
not been violated.  
 
Martingale residuals are the difference between the observed and expected number of 
events for each individual and if these are summed over all individuals at a certain time, 
then one residual can be obtained for each failure time.  Martingale residuals can be used 
to evaluate functional forms of covariates and well as to test the Cox proportionality 
assumption.17 They usually are converted to deviance residuals so they are more 
symmetrically centered around zero and if they are plotted against the covariates, they 
should show a relatively random pattern around the mean of zero to show that the 
functional form or proportionality assumption is valid. 
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Lastly, results need to be evaluated for stability meaning covariates need to be evaluated 
over an appropriate range to see if their modification changes the overall outcome of the 
study. If the covariate has a determined range (e.g. sensitivity ranges from 95-98%), then 
deterministic sensitivity analyses can be employed where the sensitivity is varied in a 
step-wise fashion over its entire range. If the covariate and its range is better described by 
a probability distribution rather than specific values (e.g. probability of expiring at a 
certain time based on exposure and patient characteristics), then probabilistic sensitivity 
analyses can be employed. Regardless of type of sensitivity analysis used, it is important 
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CHAPTER SIX – HEALTH POLICY IN RENAL TRANSPLANTATION 
 
The goal of many health-related studies is to improve the health of a population. The 
process through which that population health is improved is generally through health 
policy.  The World Health Organization defines health policy as the pursuit of health care 
goals within the context of a future health vision through building consensus among 
stakeholders.1 
 
While some scientific studies (e.g. comparisons of outcomes between different 
treatments) may not have policy implications as the health market will adjust according 
to price and outcome advantage through patient/provider preference and insurance 
coverage, there are some studies that need public policy to champion their cause in 
improving population health (e.g. smoking cessation campaigns). Public policy is brought 
about by government officials addressing public health problems that are felt to be 
unacceptable to the official or to the public in general.2 Governmental intervention many 
times is in the form of distribution, redistribution or regulation in order to direct or 
influence the decisions, actions or behaviors of others in the face of market failures such 
as monopolies, negative or positive externalities, and information failures, to name a few 
instances. Public policies can originate in the legislative, executive, or judicial branches 
of government.  When these public policies are centered around health, they are referred 
to as health policy.  Health policy, by necessity due to the large field of health care, deals 
with topics including health care research, health systems, health care delivery, access to 
care, and quality of care to name just a very few. 
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The government works at several levels including national, state and local and functions 
through policies affecting guidance, operations or funding. In order to effectively 
promote change in the government through policy, policy must be made with these 
factors in mind recognizing that neglect of any one of the above-stated factors can lead to 
policy failure.  National policies provide necessary guidance and leadership, operational 
policies are the means for implementing policies, and funding policies assure the 
financial viability of a policy.3 It is also important to ensure the ability to “scale-up” a 
policy intervention.  Scaling up is a deliberate effort to move from pilot testing an idea on 
a defined population to the general population at a reasonable rate and then to assure 
longevity of that intervention.4  
 
Evidence-based policy has as a goal the adopting of public policy based on scientifically 
established objective data.  This concept is the same as that of evidence-based medicine 
where the delivery of medical care is based on practices established by scientific studies. 
Of course, some issues are not well described by universally accepted quantitative 




There a number of government and non-government agencies that play key roles in the 
care of end-stage renal patients. These include: Congress, which has been involved in 
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kidney transplantation for decades (Social Security Act, 1972; NOTA, 1984), the U.S. 
Department of Health and Human Services (HHS)5 that awarded the first 
contract to UNOS to operate the OPTN,  the United Network for Organ Sharing (UNOS), 
a private, non-profit organization tasked with operating the Organ Procurement and 
Transplantation Network, managing the wait list, arranging recipient and donor matches 
and maintaining a database, and the Organ Procurement Organizations (OPO’s), which 
are non-profit organizations that evaluate and procure organs from deceased donors. 
 
The work in this thesis lends itself to affecting change that would be made at the national 
level. First, the scoping review may provide evidence as to where that research might be 
best carried out by virtue of the gaps analysis although there was no formal comparative- 
or cost-effectiveness evaluation in the scoping review of the impact of the research in the 
different areas. However, the methodology of assessing the scope of the literature to 
determine research gaps may lead to operational policy change in funding mechanisms at 
the national level where grant funds would only be dispersed after a researcher conducted 
or reported a formal gaps analysis. The purpose of this would be to assure that research is 
being more efficiently carried out in areas of need rather than performing duplicated 
research in areas already saturated with studies. 
 
Second, the cost-effectiveness paper on screening lends itself to national policy change at 
the OPTN level. In seeking to optimize outcomes (e.g. balancing utilizing the most non-
infected organs and avoiding use of infected organs) at the lowest cost, the OPTN may 
decide to change national high-risk donor organ screening practices. The results of this 
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paper would have to be corroborated by further research and then it would be up to the 
working council of the OPTN to change the national screening policy or not. 
 
Third, the Markov model paper also has the potential to affect policy at the OPTN level.  
While it has been known that marginal kidneys have benefit to those on the waiting list, it 
has not been elucidated by KDPI and patient phenotypes. The OPTN may form waiting 
lists by KDPI level so that individuals consent to receive certain KDPI level kidneys as 
they do now for high-infectious risk organs. In this manner, the discussion of risk and 
benefits of certain organs for an individual patient can be had prior to transplantation 
offer and potentially decrease the last-minute discussions of the risks of high KDPI 
organs, decrease the turn down of KDPI organs and subsequently decrease the increased 
cold ischemic time associated with organ turn down. 
 
While the results of this thesis lend themselves to national guideline changes, it is still 
important that all of these different organizations involved in kidney transplantation be 
accounted for in order for the policy to be effective. It is recognized that establishing 
consensus among so many organizations and the government can be monumental as 
described by one participant in the passage of the Norwood Act of 2007 who said that 
“(t)hose involved in (that) process can attest that the passage of the Norwood Act was a 
herculean endeavor – for a modality that had no opposition from anyone in the medical 
community, the general public, or Congress.”6 There are an abundance of stakeholder 
organizations that can be called upon for support in policy efforts in the kidney 
transplantation community.  A few of these organizations include the National Kidney 
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Foundation, the American Society of Transplant Surgeons, the American Society of 
Transplantation, the Association of Organ Procurement Organizations and the Transplant 
Recipients International Organization.	  
 
Important legislative work has been done recently by Johns Hopkins researchers and 
clinicians in the field of kidney transplantation. First, the Charlie W. Norwood Living 
Organ Donation Act of 20077 amends NOTA (1984) in specifically stating that human 
organ paired donation does not violate NOTA’s prohibition of any human organ transfer 
for human transplantation for “valuable consideration.”  The policy change was prompted 
by Johns Hopkins researcher clinician, Dr. Dorry Segev, who published research across 
years and journals with multiple collaborators that showed the benefit of increased kidney 
transplants each year.8,9 In addition, the Congressional Budget Office found that the 
legislation would save Medicare $500M over 10 years and the U.S. Justice Department 
issued a legal opinion at the request of the U.S. HSS stating that paired donations did not 
qualify as “valuable consideration.”10  
 
Second, the conception and passing of the HIV Organ Policy Equity (HOPE) Act of 
201311 was also instigated by the research of Dr. Dorry Segev. The policy specifically 
amended the Public Health Service Act to repeal the OPTN directive that HIV positive 
organs from deceased donors could not be acquired or used in transplantation.11 This 
policy was based on research in the potential pool of HIV-infected deceased donors that 
was estimated to be approximately 500-600 donors per year. It was argued that the use of 
those organs would significantly decrease the wait time for those with and without HIV 
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on the kidney transplant waitlist and thereby significantly decrease the associated 
mortality, morbidity and cost of kidney transplant candidates remaining on the waitlist.12 
 
In summary, the three papers in this thesis serve to elucidate the more efficient use of 
research and utilization of marginal organ donations. The results of each paper have 
potential policy implication that would serve to improve research efforts and increase the 
survival and QALYs while potentially simultaneously decreasing the cost of care of those 
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